patients,were,diagnosed_with_PA_at_earlier_age_than_patients
study,collect_family_history_in,large_cohort_of_patients
Overall_46.6_%,had,family_member_affected
patients,were,diagnosed_with_PA_at_earlier_age_than_patients_with_negative_family_history
%,had,family_member_affected
Lung_cancer,was_reported_in,12.1_%_of_patients_with_prolactinomas
patients,are,diagnosed
third-degree_relatives,were,reported_in_higher_proportion_of_patients
colon_cancers,diagnosed_compared_with,patients_diagnosed
patients,is_with,non-functioning_pituitary_adenomas
study,collect_family_history_in,large_cohort_of_patients_with_pituitary_adenomas
Lung_cancer,was_reported_in,12.1_%_of_patients_with_prolactinomas_higher
Female_patients,are,commonly_diagnosed
study,collect_family_history_in,cohort_of_patients_in_outpatient_clinic
patients,were,diagnosed_with_PA_at_earlier_age
second_relative,had_diagnosed_later_in,life
Lung_cancer,was_reported_in,12.1_%_higher
patients,diagnosed_later_in,life
patients,were,diagnosed_with_PA_at_age
Female_patients,are_commonly_diagnosed_before,age_of_25_years
results,suggest,familial_cancer_clustering
patients,are,commonly_diagnosed
patients,are_commonly_diagnosed_before,age_of_25_years
study,collect_family_history_in,cohort_of_patients_with_pituitary_adenomas_in_outpatient_clinic
study,collect_family_history_in,cohort_of_patients
Lung_cancer,was_reported_in,12.1_%_higher_than_in_families
relative,had_diagnosed_in,life
third-degree_relatives,were,reported_in_higher_proportion_of_patients_with_PA
patients,were,diagnosed
People,are_at,risk
acromegaly,was_higher_than,than_families
cancer,was_reported_with,type_of_PA.
patients,are_more_commonly_diagnosed_before,age_of_25_years
Lung_cancer,was_reported_in,12.1_%_higher_than_in_families_of_NFPA_patients
Lung_cancer,was_reported_in,12.1_%_of_patients_significantly_higher_than_in_families_of_NFPA_patients
patients,were_diagnosed_at,age_than_patients_with_negative_family_history
patients,were_diagnosed_at,earlier_age_than_patients_with_family_history
results,suggest,cancer_clustering
acromegaly,was_higher_than,than_families_of_patients_with_adenomas
Lung_cancer,was_reported_in,12.1_%_of_patients_significantly_higher
patients,is_with,prolactinoma
colon_cancers,diagnosed_compared_with,patients_with_PA_diagnosed_later
acromegaly,was_significantly_higher_than,than_families_of_patients_with_non-functioning_adenomas
colon_cancers,diagnosed_compared_with,patients_with_PA
relatives,were,reported_in_significantly_higher_proportion_of_patients
colon_cancers,diagnosed_compared_with,patients_diagnosed_later_in_life
study,collect_family_history_in,large_cohort_of_patients_in_outpatient_clinic
%,had,family_member_affected_with_cancer
Lung_cancer,was_reported_in,12.1_%_of_patients_higher_than_in_families_of_NFPA_patients
p,=,0.004
Lung_cancer,was_reported_in,12.1_%_of_patients_with_prolactinomas_significantly_higher
relative,had_diagnosed_later_in,life
Breast_cancer,was,reported
acromegaly,was_significantly_higher_than,than_families_of_patients_with_pituitary_adenomas
research,is,needed
patients,are_more_commonly_diagnosed_before,age
patients,are,more_commonly_diagnosed
patients,is_in,outpatient_clinic
colon_cancers,diagnosed_before,age_of_25_years
colon_cancers,diagnosed_compared_with,patients_with_PA_diagnosed_later_in_life
relatives,were,reported_in_proportion_of_patients_with_PA
colon_cancers,diagnosed_compared_with,patients_with_PA_diagnosed
study,collect_family_history_in,cohort
relatives,were,reported_in_higher_proportion
Female_patients,are_commonly_diagnosed_before,age
study,collect,family_history
colon_cancers,diagnosed_before,age
Further_research,is,needed
acromegaly,was_higher_than,than_families_of_patients_with_non-functioning_pituitary_adenomas
second_relative_higher,had_diagnosed_later_in,life
1062_patients,is_with,PA
patients,were_diagnosed_at,earlier_age
relatives,were,reported_in_higher_proportion_of_patients
Overall_%,had,family_member_affected
colon_cancers,diagnosed_compared_with,patients_diagnosed_later
young_patients,is_with,PA
study,collect_family_history_in,large_cohort_of_patients_with_pituitary_adenomas_in_outpatient_clinic
study,collect_family_history_in,large_cohort_of_patients_with_adenomas_in_outpatient_clinic
Lung_cancer,was_reported_in,12.1_%_of_patients_higher
association,is_In,particular
patients,is_with,prolactinomas
acromegaly,was_significantly_higher_than,than_families_of_patients
second_relative,had_diagnosed_in,life
patients,are_commonly_diagnosed_before,age
familial_cancer_clustering,is_in,patients_with_prolactinoma
Lung_cancer,was,reported
third-degree_relatives,were,reported_in_higher_proportion
patients,is_with,positive_family_history_of_malignancy
patients,were,diagnosed_with_PA_at_age_than_patients_with_family_history
Lung_cancer,was_reported_in,12.1_%_of_patients
patients,were,diagnosed_with_PA_at_age_than_patients
Overall_46.6_%,had,family_member_affected_with_cancer
Lung_cancer,was_reported_in,12.1_%_of_patients_with_prolactinomas_higher_than_in_families_of_NFPA_patients
relative_higher,had_diagnosed_in,life
they,have,family_history_of_cancer
second_relative_higher,had_diagnosed_in,life
Lung_cancer,was_reported_in,12.1_%_of_patients_with_prolactinomas_significantly_higher_than_in_families_of_NFPA_patients
Female_patients,are_more_commonly_diagnosed_before,age
relatives,were,reported_in_proportion_of_patients
study,collect_family_history_in,cohort_of_patients_with_pituitary_adenomas
patients,were,diagnosed_with_PA_at_earlier_age_than_patients_with_family_history
study,collect_family_history_in,large_cohort_of_patients_with_adenomas
colon_cancers,diagnosed_compared_with,patients_diagnosed_in_life
colon_cancers,diagnosed_compared_with,patients_with_PA_diagnosed_in_life
Overall_%,had,family_member
Female_patients,are_more_commonly_diagnosed_before,age_of_25_years
they,have,family_history
patients,were_diagnosed_at,age
patients,were_diagnosed_with,PA
patients,is_with,pituitary_adenomas
results,suggest,cancer_clustering_in_patients_with_prolactinoma
third-degree_relatives,were,reported_in_significantly_higher_proportion_of_patients
Female_patients,are,diagnosed
patients,were_diagnosed_at,earlier_age_than_patients
Colorectal_cancer,is_in,relatives_of_patients_with_PA
third-degree_relatives,were,reported_in_significantly_higher_proportion_of_patients_with_PA
relatives,were,reported_in_significantly_higher_proportion_of_patients_with_PA
study,collect,family_history_of_cancer
Lung_cancer,was_reported_in,12.1_%_significantly_higher_than_in_families_of_NFPA_patients
Colorectal_cancer,was_reported_with,type_of_PA.
patients,are_diagnosed_before,age
Female_patients,are_diagnosed_before,age_of_25_years
patients,diagnosed_in,life
People,are_at,higher_risk_for_malignancy
acromegaly,was_significantly_higher_than,than_families_of_patients_with_adenomas
acromegaly,was_higher_than,than_families_of_patients
third-degree_relatives,were,reported_in_proportion
study,collect_family_history_in,cohort_of_patients_with_adenomas_in_outpatient_clinic
Lung_cancer,was_reported_in,12.1_%_of_patients_with_prolactinomas_higher_than_in_families
patients,are_diagnosed_before,age_of_25_years
acromegaly,was_significantly_higher_than,than_families
they,have,strong_family_history
relatives,were,reported
acromegaly,was_higher_than,than_families_of_patients_with_non-functioning_adenomas
46.6_%,had,family_member_affected
People,are_at,higher_risk
acromegaly,was_higher_than,than_families_of_patients_with_pituitary_adenomas
results,suggest,familial_cancer_clustering_in_patients
Lung_cancer,is_in,family_members
third-degree_relatives,were,reported_in_proportion_of_patients
Female_patients,is_with,prolactinoma
Lung_cancer,was_reported_in,12.1_%
Lung_cancer,was_reported_in,12.1_%_of_patients_with_prolactinomas_significantly_higher_than_in_families
patients,is_with,PA
relatives,were,reported_in_higher_proportion_of_patients_with_PA
colon_cancers,diagnosed_compared_with,patients
46.6_%,had,family_member
patients,were_diagnosed_at,earlier_age_than_patients_with_negative_family_history
Lung_cancer,was_reported_in,12.1_%_significantly_higher
patients,is_with,negative_family_history
Female_patients,are_diagnosed_before,age
Lung_cancer,was_reported_in,12.1_%_of_patients_higher_than_in_families
third-degree_relatives,were,reported_in_significantly_higher_proportion
Overall_46.6_%,had,family_member
they,have,strong_family_history_of_cancer
People,are_at,risk_for_malignancy
acromegaly,was,significantly_higher
46.6_%,had,family_member_affected_with_cancer
patients,were,diagnosed_with_PA_at_age_than_patients_with_negative_family_history
results,suggest,cancer_clustering_in_patients
acromegaly,was_significantly_higher_than,than_families_of_patients_with_non-functioning_pituitary_adenomas
third-degree_relatives,were,reported_in_proportion_of_patients_with_PA
patients,were_diagnosed_at,age_than_patients
acromegaly,was,higher
Lung_cancer,was_reported_in,12.1_%_significantly_higher_than_in_families
lung,is_in,second
relatives,were,reported_in_proportion
relatives,were,reported_in_significantly_higher_proportion
Lung_cancer,was_reported_in,12.1_%_of_patients_significantly_higher_than_in_families
strong_association,is_In,particular
patients,were_diagnosed_at,age_than_patients_with_family_history
results,suggest,familial_cancer_clustering_in_patients_with_prolactinoma
third-degree_relatives,were,reported
study,collect_family_history_from,years_2005-2017
study,collect_family_history_in,cohort_of_patients_with_adenomas
study,collect_family_history_in,large_cohort
Overall_%,had,family_member_affected_with_cancer
relative_higher,had_diagnosed_later_in,life
Breast_cancer,is_in,family_members
Female_patients,are,more_commonly_diagnosed
%,had,family_member
Patients,were_stratified_based_on,presence_of_disease
cases,were,analyzed
Management,often_involves,radiation
retrospective_chart_review,was_conducted_of,patients_with_breast_cancer
follow-up,was,25_months
Radiotherapy,provided,symptom_control
chart_review,was_conducted_of,patients_with_advanced_breast_cancer
disease,is,present_radiotherapy
Radiotherapy,provided,response_in_patients_in_study
Radiotherapy,provided,good_response_in_most_patients_in_study
metastatic_disease,is,present_radiotherapy
chart_review,was_conducted_of,patients_with_unresected_advanced_breast_cancer
metastatic_disease,with_cases_is,56_%
response,is_in,most_patients
metastatic_disease,is,When_present_locoregional_radiotherapy
retrospective_chart_review,was_conducted_of,patients_with_locally_advanced_breast_cancer
role,is_in,patients_with_LABC
patients,is_with,unresected_locally_advanced_breast_cancer
We,reviewed,our_experience_of_high-dose_radiotherapy
chart_review,was_conducted_of,patients_with_locally_advanced_breast_cancer
Median_follow-up,was,25_months
Management,often_involves,neoadjuvant_therapy_surgery
24_cases,is_with,metastatic_disease_on_presentation
chart_review,was,conducted
Management,often_involves,neoadjuvant_systemic_therapy_surgery
tumour,remains_following,systemic_therapy_radiotherapy
Radiotherapy,provided,good_response_in_patients_in_study
Patients,were,stratified
Patients,were_stratified_based_on,presence
Forty-three_cases,were,analyzed
Management,involves,radiation
bleeding,improved_in,54_%
retrospective_chart_review,was_conducted_of,patients_with_unresected_locally_advanced_breast_cancer
disease,is,locoregional_radiotherapy
disease,is,When_radiotherapy
We,reviewed,our_experience_of_radiotherapy
Ulceration,improved_in,54_%
primary_tumour,remains,unresectable
metastatic_disease,is,radiotherapy
disease,is,When_present_radiotherapy
Management,involves,therapy_surgery
Median_follow-up,was,25_months_from_diagnosis
metastatic_disease,is,When_locoregional_radiotherapy
We,reviewed,our_experience
Patients,were_stratified_based_on,presence_of_metastatic_disease
most_patients,is_in,study
Management,involves,systemic_therapy_surgery
disease,is,When_locoregional_radiotherapy
metastatic_disease,is,locoregional_radiotherapy
bleeding,improved_following,radiotherapy
Patients,were_stratified_based_on,presence_of_disease_at_presentation
disease,is,present_locoregional_radiotherapy
primary_tumour,remains_following,therapy_radiotherapy
24_applicable_cases,of_13_is,54_%
retrospective_chart_review,was_conducted_of,patients_with_advanced_breast_cancer
patients,is_with,LABC
Patients,were_stratified_based_on,presence_at_presentation
chart_review,was_conducted_of,patients
disease,is,When_present_locoregional_radiotherapy
Management,involves,neoadjuvant_systemic_therapy_surgery
tumour,remains,unresectable
chart_review,was_conducted_of,patients_with_unresected_locally_advanced_breast_cancer
Ulceration,improved_following,radiotherapy
primary_tumour,remains_following,systemic_therapy_radiotherapy
tumour,remains_following,therapy_radiotherapy
metastatic_disease,is,When_present_radiotherapy
Patients,were_stratified_based_on,presence_of_metastatic_disease_at_presentation
Management,often_involves,systemic_therapy_surgery
metastatic_disease,is,present_locoregional_radiotherapy
chart_review,was_conducted_of,patients_with_unresected_breast_cancer
Patient_demographics_disease_characteristics,were,recorded
Management,involves,neoadjuvant_therapy_surgery
retrospective_chart_review,was_conducted_of,patients
Management,often_involves,therapy_surgery
follow-up,was,25_months_from_diagnosis
chart_review,was_conducted_of,patients_with_breast_cancer
retrospective_chart_review,was_conducted_of,patients_with_unresected_breast_cancer
disease,is,radiotherapy
retrospective_chart_review,was_conducted_of,patients_with_unresected_advanced_breast_cancer
metastatic_disease,is,When_radiotherapy
Radiotherapy,provided,response_in_most_patients_in_study
retrospective_chart_review,was,conducted
we,systematically_analyzed,glycosylation_of_membrane_type_MR
membrane_type_mannose_receptor,was_expressed_in,breast_cancer_patients_serum
Breast_cancer,is_recognized_as,cancer_in_patients_worldwide
five,were,newly_identified
we,analyzed,glycosylation
we,systematically_analyzed_glycosylation_by,mass_spectrometry
Breast_cancer,is_recognized_as,heterogeneous_cancer_in_patients_worldwide
we,analyzed,glycosylation_of_membrane_type_MR
membrane_type_MR,was_expressed_in,four_types_of_breast_cancer
glycosylation_sites,were,identified
five,were_identified_among,them
heterogeneous_cancer,is_in,female_patients_worldwide
five,were,among_them_newly_identified_in_study
we,systematically_analyzed,glycosylation
barcode_mode,was,established
membrane_type_MR,was,differentially_expressed
Breast_cancer,is_recognized_as,heterogeneous_cancer_in_female_patients
we,assume,expressed_in_four_types
discovery,is,urgently_needed
we,analyzed_glycosylation_by,mass_spectrometry
we,Therefore_systematically_analyzed,glycosylation_of_membrane_type_MR
we,discovered_According_to,our_molecular_biology_experiment_data
we,discovered_According_to,our_preliminary_biology_experiment_data
membrane_type_MR,be,used
membrane_type_MR,was_differentially_expressed_in,four_types
Breast_cancer,is_recognized_as,cancer
we,Therefore_analyzed,glycosylation
membrane_type_mannose_receptor,was,expressed
five,were_newly_identified_in,study
Breast_cancer,is_recognized_as,cancer_in_female_patients_worldwide
we,Therefore_analyzed,glycosylation_of_membrane_type_MR
we,assume,expressed_in_four_types_of_breast_cancer
we,Therefore_analyzed_glycosylation_by,mass_spectrometry
discovery,is,needed
Six_glycosylation_sites,were,identified
Breast_cancer,is_recognized_as,heterogeneous_cancer_in_female_patients_worldwide
we,discovered_According_to,our_biology_experiment_data
membrane_type_MR,was_differentially_expressed_in,four_types_of_breast_cancer
Breast_cancer,is_recognized_as,heterogeneous_cancer_in_patients
membrane_type_MR,was_expressed_in,four_types
we,assume,differentially_expressed_in_four_types_of_breast_cancer
Breast_cancer,is_recognized_as,cancer_in_female_patients
five,were_identified_in,study
we,discovered_According_to,our_preliminary_molecular_biology_experiment_data
five,were_newly_identified_among,them
five,were,identified
membrane_type_MR,was,expressed
membrane_type_MR,distinguish,four_types
we,assume,differentially_expressed
five,were,among_them_identified_in_study
we,assume,differentially_expressed_in_four_types
membrane_type_MR,distinguish,four_types_of_breast_cancer
we,Therefore_systematically_analyzed_glycosylation_by,mass_spectrometry
Breast_cancer,is_recognized_as,cancer_in_patients
Breast_cancer,is,recognized
we,Therefore_systematically_analyzed,glycosylation
barcode_mode,was_established_based_on,six_glycosylation_sites
we,assume,expressed
Breast_cancer,is_recognized_as,heterogeneous_cancer
membrane_type_mannose_receptor,was_highly_expressed_in,breast_cancer_patients_serum
membrane_type_mannose_receptor,was,highly_expressed
we,defined,low-dose_aspirin_use
we,association_between,use_of_aspirin
we,defined,aspirin_use
Cox_proportional_hazard_regression_models,calculate_confidence_intervals_for,association_between_post-diagnosis_aspirin_use
Cox_proportional_hazard_regression_models,were,used
we,defined,post-diagnosis_aspirin_use
Observational_studies,have_provided,results
Cox_proportional_hazard_regression_models,calculate_hazard_ratios_for,association
1_444_women,developed_CBC_during,median_follow-up_of_4.8_years
we,examined,association_between_post-diagnosis_use_of_low-dose_aspirin
we,examined,association_between_post-diagnosis_use_of_aspirin
we,defined_aspirin_use_In,main_analysis
Cox_proportional_hazard_regression_models,calculate,HRs
Information,was_obtained_from,registries
Cox_proportional_hazard_regression_models,calculate_hazard_ratios_for,association_between_low-dose_aspirin_use
we,examined,association
women,developed_CBC_during,median_follow-up_of_4.8_years
women,developed,CBC
we,association_between,post-diagnosis_use
we,defined_aspirin_use_In,analysis
1_444_women,developed_CBC_during,median_follow-up
Cox_hazard_regression_models,calculate_hazard_ratios_for,association_between_aspirin_use
Cox_proportional_hazard_regression_models,calculate_hazard_ratios_for,association_between_post-diagnosis_low-dose_aspirin_use
studies,have_provided,results
Cox_proportional_hazard_regression_models,calculate,hazard_ratios
Cox_proportional_hazard_regression_models,calculate,CIs
Cox_hazard_regression_models,calculate_hazard_ratios_for,association_between_post-diagnosis_low-dose_aspirin_use
1_444_women,developed,CBC
Cox_proportional_hazard_regression_models,calculate_confidence_intervals_for,association_between_aspirin_use
Cox_proportional_hazard_regression_models,calculate,confidence_intervals
Information,was,obtained
we,defined,time-varying_low-dose_aspirin_use
we,association_between,post-diagnosis_use_of_aspirin
we,examined,association_between_use_of_aspirin
Cox_hazard_regression_models,calculate,CIs
women,developed_CBC_during,median_follow-up
Cox_hazard_regression_models,calculate_confidence_intervals_for,association_between_post-diagnosis_low-dose_aspirin_use
Cox_hazard_regression_models,were,used
Cox_proportional_hazard_regression_models,calculate_hazard_ratios_for,association_between_aspirin_use
Cox_proportional_hazard_regression_models,calculate_confidence_intervals_for,association_between_low-dose_aspirin_use
1_444_women,developed_CBC_during,follow-up
we,applied,one-year_exposure_lag
Cox_hazard_regression_models,calculate_confidence_intervals_for,association_between_post-diagnosis_aspirin_use
Observational_studies,have_provided,inconsistent_results
Cox_hazard_regression_models,calculate_confidence_intervals_for,association_between_aspirin_use
Cox_proportional_hazard_regression_models,calculate_confidence_intervals_for,association
Cox_hazard_regression_models,calculate_confidence_intervals_for,association
Cox_hazard_regression_models,calculate,HRs
women,developed_CBC_Among,52_723_breast_cancer_patients
Cox_proportional_hazard_regression_models,calculate_confidence_intervals_for,association_between_post-diagnosis_low-dose_aspirin_use
we,association_between,post-diagnosis_use_of_low-dose_aspirin
we,defined,post-diagnosis_low-dose_aspirin_use
women,developed_CBC_during,follow-up_of_4.8_years
we,defined,time-varying_post-diagnosis_low-dose_aspirin_use
studies,have_provided,inconsistent_results
Cox_hazard_regression_models,calculate_hazard_ratios_for,association
Cox_hazard_regression_models,calculate_hazard_ratios_for,association_between_low-dose_aspirin_use
Cox_hazard_regression_models,calculate_confidence_intervals_for,association_between_low-dose_aspirin_use
Cox_proportional_hazard_regression_models,calculate_hazard_ratios_for,association_between_post-diagnosis_aspirin_use
Cox_proportional_hazard_regression_models,calculate,95_%_confidence_intervals
we,association_between,use_of_low-dose_aspirin
Cox_hazard_regression_models,calculate,hazard_ratios
we,examined,association_between_use
Cox_hazard_regression_models,calculate,confidence_intervals
Cox_hazard_regression_models,calculate,95_%_confidence_intervals
Information,was_obtained_from,nationwide_registries
1_444_women,developed_CBC_during,follow-up_of_4.8_years
we,defined,time-varying_post-diagnosis_aspirin_use
we,association_between,use
women,developed_CBC_during,follow-up
1_444_women,developed_CBC_Among,52_723_breast_cancer_patients
we,examined,association_between_use_of_low-dose_aspirin
we,applied,exposure_lag
Cox_hazard_regression_models,calculate_hazard_ratios_for,association_between_post-diagnosis_aspirin_use
we,examined,association_between_post-diagnosis_use
we,defined,time-varying_aspirin_use
Selective_binding,using,infrared_imaging_in_negative
binding,using,infrared_fluorescent_imaging_in_triple_negative
MSOT_imaging,demonstrated,accumulation_in_vitro_and_in_vivo
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_of_signal_accumulation_using_near_imaging
osteopontin-based_probe,demonstrated,binding
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_of_signal_accumulation_using_near_fluorescent_imaging
We,conjugated_osteopontin_peptide_to,fluorescent
binding,using,fluorescent_imaging_in_triple_negative
Osteopontin-750_accumulation,was,evaluated_in_vivo
Selective_binding,using,fluorescent_imaging_in_negative
it,Similarly_accumulated_in,subcutaneous_breast_tumor_in_nude_mice
MSOT_imaging,demonstrated,accumulation_of_fluorescent_osteopontin
MSOT_imaging,demonstrated,selective_accumulation_in_vitro_and_in_vivo
it,accumulated_in,subcutaneous_breast_tumor_in_nude_mice
it,accumulated_after,intravenous_administration
MSOT_imaging,demonstrated,accumulation_of_fluorescent_osteopontin_in_vitro_and_in_vivo
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_using_near_imaging
detection,would_facilitate,diagnosis_surveillance_of_response_to_treatment
it,Similarly_accumulated_in,breast_tumor_in_nude_mice
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_using_near_infrared_fluorescent_imaging
MSOT_imaging,demonstrated,accumulation_of_osteopontin_in_vitro_and
MSOT_imaging,demonstrated,accumulation_of_osteopontin_and_in_vivo
We,conjugated_osteopontin_peptide_to,fluorescent_dye
probe,demonstrated,binding_in_vitro
Improved_detection,would_facilitate,diagnosis_surveillance_of_response_to_treatment
Osteopontin-750_accumulation,using_MSOT_with,confirmation_using_near_imaging
binding,using,flow_cytometry
detection,would_facilitate,diagnosis_surveillance_of_response
MSOT_imaging,demonstrated,selective_accumulation
MSOT_imaging,demonstrated,accumulation_of_fluorescent_osteopontin_in_vitro_and
Osteopontin-750_accumulation,using_MSOT_with,confirmation_of_signal_accumulation_using_near_fluorescent_imaging
osteopontin-based_probe,demonstrated,binding_to_breast_cancer_cells
MSOT_imaging,demonstrated,accumulation_and_in_vivo
Osteopontin-750_accumulation,was,evaluated
MSOT_imaging,demonstrated,accumulation_of_osteopontin_and
We,conjugated_osteopontin_peptide_to,infrared_fluorescent
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_of_signal_accumulation_using
MSOT_imaging,demonstrated,selective_accumulation_of_fluorescent_osteopontin_and
probe,demonstrated,binding_to_breast_cancer_cells_in_vitro
binding,using,fluorescent_imaging_in_negative_in_vitro
MSOT_imaging,demonstrated,accumulation_of_fluorescent_osteopontin_and
it,accumulated_in,breast_tumor_in_mice
it,Similarly_accumulated_after,administration
it,Similarly_accumulated_in,subcutaneous_breast_tumor
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_using
Osteopontin-750_accumulation,using_MSOT_with,confirmation_of_signal_accumulation_using
binding,using,imaging_in_triple_negative_in_vitro
MSOT_imaging,demonstrated,selective_accumulation_and_in_vivo
it,Similarly_accumulated_after,intravenous_administration
Osteopontin-750_accumulation,using_MSOT_with,confirmation_using_near_infrared_fluorescent_imaging
MSOT_imaging,demonstrated,accumulation_in_vitro_and
Selective_binding,using,imaging_in_negative
binding,using,fluorescent_imaging
it,Similarly_accumulated_in,breast_tumor
MSOT_imaging,demonstrated,selective_accumulation_of_osteopontin_and_in_vivo
MSOT_imaging,demonstrated,accumulation_of_osteopontin_in_vitro_and_in_vivo
MSOT_imaging,demonstrated,selective_accumulation_of_fluorescent_osteopontin_in_vitro_and_in_vivo
binding,using,imaging
MSOT_imaging,demonstrated,selective_accumulation_and
Fluorescence_imaging_ex_vivo,confirmed,results
MSOT_imaging,demonstrated,accumulation_of_fluorescent_osteopontin_and_in_vivo
MSOT_imaging,demonstrated,accumulation
MSOT_imaging,demonstrated,accumulation_of_osteopontin
it,accumulated_in,breast_tumor_in_nude_mice
it,Similarly_accumulated_in,subcutaneous_breast_tumor_in_mice
We,conjugated,osteopontin_peptide
Osteopontin-750_accumulation,using_MSOT_with,confirmation_of_signal_accumulation_using_near_imaging
detection,would_facilitate,assessment
Osteopontin-750_accumulation,using_MSOT_with,confirmation_using_near_fluorescent_imaging
it,accumulated_after,administration
probe,demonstrated,binding_to_breast_cancer_cells
MSOT_imaging,demonstrated,selective_accumulation_of_osteopontin
binding,using,infrared_imaging_in_negative_in_vitro
Osteopontin-750_accumulation,using_MSOT_with,confirmation_using_near_infrared_imaging
binding,using,infrared_imaging_in_negative
Osteopontin-750_accumulation,using,MSOT
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_of_signal_accumulation_using_near_infrared_imaging
Osteopontin-750_accumulation,using_MSOT_with,confirmation_of_signal_accumulation_using_near_infrared_imaging
it,accumulated_in,breast_tumor
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_of_signal_accumulation_using_near_infrared_fluorescent_imaging
MSOT_imaging,demonstrated,selective_accumulation_of_fluorescent_osteopontin_in_vitro_and
binding,using,infrared_imaging_in_triple_negative_in_vitro
Osteopontin-750_accumulation,using_MSOT_with,confirmation_of_signal_accumulation_using_near_infrared_fluorescent_imaging
osteopontin-based_probe,demonstrated,binding_in_vitro
therapeutic_models,limit,toxicity
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_of_signal_accumulation
MSOT_imaging,demonstrated,selective_accumulation_of_osteopontin_in_vitro_and_in_vivo
it,Similarly_accumulated_after,intravenous_administration_of_osteopontin-750_probe
detection,would_facilitate,diagnosis_surveillance
Selective_binding,using,infrared_fluorescent_imaging_in_negative
Osteopontin-750_accumulation,using_MSOT_with,confirmation_of_signal_accumulation
binding,using,infrared_fluorescent_imaging
binding,using,infrared_fluorescent_imaging_in_triple_negative_in_vitro
probe,demonstrated,binding
binding,using,fluorescent_imaging_in_negative
binding,using,fluorescent_imaging_in_triple_negative_in_vitro
binding,using,imaging_in_triple_negative
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation
Improved_detection,would_facilitate,diagnosis_surveillance
binding,using,infrared_fluorescent_imaging_in_negative_in_vitro
infrared_fluorescent_imaging,is_in,triple_negative_in_vitro
MSOT_imaging,demonstrated,selective_accumulation_of_osteopontin_and
it,accumulated_in,subcutaneous_breast_tumor_in_mice
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_using_near_fluorescent_imaging
Improved_detection,would_facilitate,diagnosis_surveillance_of_response
Osteopontin-750_accumulation,using_MSOT_with,confirmation
MSOT_imaging,demonstrated,selective_accumulation_of_osteopontin_in_vitro_and
MSOT_imaging,demonstrated,selective_accumulation_in_vitro_and
MSOT_imaging,demonstrated,accumulation_and
Selective_binding,was,identified
binding,using,infrared_imaging_in_triple_negative
Improved_detection,would_facilitate,assessment
MSOT_imaging,demonstrated,selective_accumulation_of_fluorescent_osteopontin_and_in_vivo
models,limit,toxicity
binding,using,infrared_imaging
therapeutic_models,limit,nontarget_toxicity
it,Similarly_accumulated_after,administration_of_osteopontin-750_probe
binding,using,imaging_in_negative
it,accumulated_after,administration_of_osteopontin-750_probe
binding,using,infrared_fluorescent_imaging_in_negative
subcutaneous_breast_tumor,is_in,nude_mice
Osteopontin-750_accumulation,using_MSOT_with,confirmation_using
binding,using,imaging_in_negative_in_vitro
binding,was,identified
We,conjugated_osteopontin_peptide_to,infrared_fluorescent_dye
Selective_binding,using,imaging
it,accumulated_after,intravenous_administration_of_osteopontin-750_probe
Selective_binding,using,infrared_fluorescent_imaging
Selective_binding,using,infrared_imaging
Osteopontin-750_accumulation,using_MSOT_with,secondary_confirmation_using_near_infrared_imaging
MSOT_imaging,demonstrated,selective_accumulation_of_fluorescent_osteopontin
it,Similarly_accumulated_in,breast_tumor_in_mice
models,limit,nontarget_toxicity
Selective_binding,using,fluorescent_imaging
it,accumulated_in,subcutaneous_breast_tumor
osteopontin-based_probe,demonstrated,binding_to_breast_cancer_cells_in_vitro
Selective_binding,using,flow_cytometry
direct_relationship,was_confirmed_in,TNBC_cells
BRD4_inhibition,Moreover_induced,dose-dependent_reduction_in_BRCA1_levels
involved,was_found,involved_in_DNA_damage_regulation
homologous_recombination_pathway,induced,BRCAness_phenotype_in_BRCA1_wild-type_TNBC_cells
BRD4_inhibition,induced,reduction_in_BRCA1_levels
BRD4_regulation,explore_strategies_through,combinations_of_induction_in_BRCA1_wild-type_breast_cancer
Aims,assess,BRD4_regulation_in_homologous_recombination-mediated_DNA_repair
BRD4_regulation,explore_strategies_through,combinations_of_induction_in_BRCA1_negative_breast_cancer
Extra-Terminal_BET_proteins,regulating,gene_expression
BRD4_regulation,is_in,homologous_recombination-mediated_DNA_repair
BRD4_inhibition,Moreover_induced,reduction
increase,is_in,DNA_damage
Aims,assess,BRD4_regulation_in_DNA_repair
BRD4_pharmacological_inhibition,Moreover_induced,dose-dependent_reduction_in_BRCA1_levels
Noteworthy,being_strategy_based_on,drugs_available
BRD4_regulation,explore_strategies_through,combinations
Noteworthy,being_strategy_based_on,drugs_already_available
their_inhibition,induced,BRCAness_phenotype
BRD4_pharmacological_inhibition,induced,reduction_in_BRCA1_levels
BRD4_regulation,explore,strategies
dose-dependent_reduction,is_in,BRCA1_levels
BRD4_regulation,explore_strategies_through,combinations_of_induction_in_BRCA1_triple_breast_cancer
involved,was_recently_found,involved_in_DNA_damage_regulation
recombination_pathway,induced,BRCAness_phenotype_in_BRCA1_wild-type_TNBC_cells
their_inhibition,induced,BRCAness_phenotype_in_BRCA1_TNBC_cells
article,is_protected_by,copyright
BRD4_regulation,explore_strategies_through,combinations_of_induction_in_BRCA1_wild-type_negative_breast_cancer
Noteworthy,being,strategy
BRD4_inhibition,Moreover_induced,reduction_in_BRCA1_levels
Noteworthy,being_strategy_based_on,drugs
BRD4_regulation,explore_strategies_by_means_of,BET_inhibitors_available_in_clinic
BRD4_pharmacological_inhibition,induced,dose-dependent_reduction
BRD4_regulation,explore,clinical_strategies
BRD4_pharmacological_inhibition,Moreover_induced,dose-dependent_reduction
BRCAness_phenotype,is_in,BRCA1_wild-type_TNBC_cells
involved,be,involved
BRD4_regulation,explore,novel_strategies
BRD4_inhibition,induced,dose-dependent_reduction_in_BRCA1_levels
homologous_recombination_pathway,induced,BRCAness_phenotype
homologous_recombination_pathway,induced,BRCAness_phenotype_in_BRCA1_TNBC_cells
BRD4_regulation,explore_strategies_by_means_of,BET_inhibitors_already_available
involved,be_involved_in,DNA_damage_regulation
BRD4_pharmacological_inhibition,induced,reduction
BET_proteins,regulating,BRD4
BRD4_regulation,explore_strategies_by_means_of,BET_inhibitors_available
BRD4_inhibition,Moreover_induced,dose-dependent_reduction
article,is,protected
Aims,assess,BRD4_regulation
relationship,was,confirmed
BRCAness_phenotype,is_in,TNBC_cells
involved,was,recently_found
recombination_pathway,induced,BRCAness_phenotype
Bromodomain,are,involved
BRD4_regulation,explore_strategies_through,combinations_of_induction_in_BRCA1_wild-type_triple_breast_cancer
direct_relationship,was,confirmed
pharmacological_induction,is_in,BRCA1_wild-type_triple_negative_breast_cancer
BRD4_regulation,explore_strategies_through,combinations_of_induction_in_BRCA1_triple_negative_breast_cancer
BRD4_pharmacological_inhibition,Moreover_induced,reduction
BRD4_regulation,explore_strategies_by_means_of,BET_inhibitors_already_available_in_clinic
involved,was_recently_found,involved
BRD4_regulation,explore_strategies_through,combinations_of_induction_in_BRCA1_wild-type_triple_negative_breast_cancer
BRD4_regulation,explore,novel_clinical_strategies
BRD4_pharmacological_inhibition,induced,dose-dependent_reduction_in_BRCA1_levels
relationship,was_confirmed_in,TNBC_cells
BRD4_pharmacological_inhibition,Moreover_induced,reduction_in_BRCA1_levels
involved,was_found,involved
BRD4_regulation,explore_strategies_through,combinations_of_induction
BRD4_inhibition,induced,dose-dependent_reduction
Aims,assess,BRD4_regulation_in_recombination-mediated_DNA_repair
involved,was,found
Extra-Terminal_BET_proteins,regulating,BRD4
Aims,assess,BRD4_regulation_in_homologous_DNA_repair
recombination_pathway,induced,BRCAness_phenotype_in_BRCA1_TNBC_cells
BRD4_regulation,explore_strategies_by_means_of,BET_inhibitors
their_inhibition,induced,BRCAness_phenotype_in_BRCA1_wild-type_TNBC_cells
Bromodomain,are,historically_involved
BET_proteins,regulating,gene_expression
BRD4_regulation,explore_strategies_through,combinations_of_induction_in_BRCA1_breast_cancer
BRD4_inhibition,induced,reduction
novel_technique,Finally_is_emerging_as,precise_tool_for_treatment_of_cancer
technique,Finally_is_emerging_as,tool_for_treatment_of_cancer_including_BC
novel_technique,is_emerging_as,tool
technique,is_emerging_as,precise_tool_for_targeted_treatment_of_cancer_including_BC
technique,is_emerging_as,precise_tool_for_treatment
novel_technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment
novel_powerful_technique,Finally_is_emerging_as,precise_tool_for_treatment_of_cancer_including_BC
novel_powerful_technique,is_emerging_as,tool_for_targeted_treatment
components,include,DNA_repair_pathway_components
novel_powerful_technique,Finally_is_emerging_as,tool_for_targeted_treatment_of_cancer_including_BC
technique,is_emerging_as,tool_for_treatment
novel_powerful_technique,Finally_is_emerging_as,precise_tool_for_treatment
technique,is_emerging_as,tool_for_treatment_of_cancer_including_BC
novel_technique,is_emerging_as,tool_for_treatment_of_cancer_including_BC
Breast_cancer,is_most_common_cancer_among,women
novel_technique,is_emerging_as,tool_for_targeted_treatment_of_cancer
approaches,are,are_developed
development,has_led_to,decreases_in_BC_mortality_rates
novel_technique,Finally_is_emerging_as,tool_for_treatment
powerful_technique,Finally_is_emerging_as,precise_tool_for_treatment_of_cancer
technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment_of_cancer_including_BC
technique,Finally_is_emerging_as,precise_tool_for_treatment
novel_technique,Finally_is_emerging_as,tool_for_treatment_of_cancer_including_BC
inhibitor/mimic_approaches,are,are_developed_for_treatment_of_BC
powerful_technique,Finally_is_emerging_as,tool_for_targeted_treatment_of_cancer_including_BC
novel_technique,Finally_is_emerging_as,tool_for_targeted_treatment
decreases,is_in,BC_mortality_rates
Breast_cancer,is,common_cancer
technique,Finally_is_emerging_as,tool
powerful_technique,is_emerging_as,precise_tool_for_treatment
novel_technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment_of_cancer
40_000_deaths,is_in,United_States
novel_technique,is_emerging_as,precise_tool_for_targeted_treatment_of_cancer_including_BC
technique,Finally_is_emerging_as,tool_for_treatment_of_cancer
powerful_technique,is_emerging_as,precise_tool
technique,Finally_is_emerging_as,precise_tool_for_treatment_of_cancer
novel_powerful_technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment
novel_powerful_technique,is_emerging_as,tool_for_targeted_treatment_of_cancer
technique,is_emerging_as,precise_tool_for_targeted_treatment_of_cancer
powerful_technique,is_emerging_as,tool_for_targeted_treatment
powerful_technique,Finally_is_emerging_as,tool
novel_powerful_technique,is_emerging_as,precise_tool_for_targeted_treatment_of_cancer
inhibitor/mimic_approaches,are,are_developed
novel_technique,is_emerging_as,tool_for_targeted_treatment
novel_technique,is_emerging_as,precise_tool
novel_technique,Finally_is_emerging_as,tool
technique,is_emerging_as,tool_for_treatment_of_cancer
development,has_led_In,decades
powerful_technique,is_emerging_as,tool_for_treatment_of_cancer_including_BC
approaches,are,are_developed_for_treatment_of_BC
powerful_technique,is_emerging_as,precise_tool_for_targeted_treatment_of_cancer
Breast_cancer,is,most_common_cancer
powerful_technique,Finally_is_emerging_as,tool_for_targeted_treatment
novel_powerful_technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment_of_cancer_including_BC
novel_powerful_technique,is_emerging_as,tool
powerful_technique,Finally_is_emerging_as,precise_tool_for_treatment
powerful_technique,is_emerging_as,precise_tool_for_targeted_treatment_of_cancer_including_BC
powerful_technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment
powerful_technique,Finally_is_emerging_as,tool_for_treatment_of_cancer
technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment_of_cancer
novel_technique,Finally_is_emerging_as,tool_for_targeted_treatment_of_cancer
technique,is_emerging_as,tool_for_targeted_treatment
novel_powerful_technique,Finally_is_emerging_as,precise_tool_for_treatment_of_cancer
novel_powerful_technique,is_emerging_as,precise_tool_for_targeted_treatment_of_cancer_including_BC
novel_technique,is_emerging_as,precise_tool_for_treatment_of_cancer_including_BC
novel_powerful_technique,is_emerging_as,precise_tool
novel_powerful_technique,Finally_is_emerging_as,tool
novel_powerful_technique,Finally_is_emerging_as,tool_for_treatment_of_cancer_including_BC
novel_technique,Finally_is_emerging_as,tool_for_treatment_of_cancer
novel_technique,Finally_is_emerging_as,tool_for_targeted_treatment_of_cancer_including_BC
novel_powerful_technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment_of_cancer
technique,is_emerging_as,tool_for_targeted_treatment_of_cancer_including_BC
novel_powerful_technique,Finally_is_emerging_as,tool_for_treatment_of_cancer
powerful_technique,is_emerging_as,precise_tool_for_targeted_treatment
novel_technique,is_emerging_as,precise_tool_for_treatment
novel_technique,is_emerging_as,tool_for_treatment
powerful_technique,is_emerging_as,precise_tool_for_treatment_of_cancer_including_BC
novel_technique,Finally_is_emerging_as,precise_tool_for_treatment
components,include,ErbB_family_members_Ras/MAPK_pathway_components_VEGF_family_members
novel_technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment_of_cancer_including_BC
powerful_technique,Finally_is_emerging_as,precise_tool
novel_powerful_technique,is_emerging_as,tool_for_treatment_of_cancer_including_BC
powerful_technique,is_emerging_as,precise_tool_for_treatment_of_cancer
novel_powerful_technique,Finally_is_emerging_as,tool_for_targeted_treatment
powerful_technique,is_emerging_as,tool
technique,Finally_is_emerging_as,tool_for_treatment
novel_powerful_technique,Finally_is_emerging_as,precise_tool
technique,is_emerging_as,tool_for_targeted_treatment_of_cancer
powerful_technique,Finally_is_emerging_as,tool_for_treatment
technique,is_emerging_as,tool
Breast_cancer,is,cancer
Breast_cancer,is_common_cancer_among,women
technique,is_emerging_as,precise_tool_for_treatment_of_cancer
powerful_technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment_of_cancer_including_BC
powerful_technique,is_emerging_as,tool_for_treatment_of_cancer
technique,Finally_is_emerging_as,tool_for_targeted_treatment
technique,is_emerging_as,precise_tool_for_treatment_of_cancer_including_BC
inhibitor/mimic_approaches,are,are_developed_for_treatment
technique,is_emerging_as,precise_tool
technique,Finally_is_emerging_as,tool_for_targeted_treatment_of_cancer
novel_powerful_technique,Finally_is_emerging_as,tool_for_treatment
development,has_led_In,previous_decades
technique,Finally_is_emerging_as,tool_for_targeted_treatment_of_cancer_including_BC
novel_powerful_technique,Finally_is_emerging_as,tool_for_targeted_treatment_of_cancer
novel_technique,is_emerging_as,tool_for_targeted_treatment_of_cancer_including_BC
powerful_technique,Finally_is_emerging_as,tool_for_treatment_of_cancer_including_BC
novel_technique,Finally_is_emerging_as,precise_tool_for_treatment_of_cancer_including_BC
novel_technique,is_emerging_as,precise_tool_for_targeted_treatment_of_cancer
powerful_technique,Finally_is_emerging_as,tool_for_targeted_treatment_of_cancer
novel_powerful_technique,is_emerging_as,precise_tool_for_treatment_of_cancer_including_BC
novel_powerful_technique,is_emerging_as,precise_tool_for_targeted_treatment
novel_powerful_technique,is_emerging_as,precise_tool_for_treatment
Breast_cancer,is_cancer_among,women
development,has_led_to,decreases
technique,Finally_is_emerging_as,precise_tool
powerful_technique,is_emerging_as,tool_for_treatment
novel_powerful_technique,is_emerging_as,tool_for_treatment_of_cancer
novel_powerful_technique,is_emerging_as,tool_for_targeted_treatment_of_cancer_including_BC
powerful_technique,Finally_is_emerging_as,precise_tool_for_treatment_of_cancer_including_BC
novel_technique,is_emerging_as,precise_tool_for_targeted_treatment
it,is,responsible
powerful_technique,is_emerging_as,tool_for_targeted_treatment_of_cancer_including_BC
technique,Finally_is_emerging_as,precise_tool_for_treatment_of_cancer_including_BC
powerful_technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment_of_cancer
novel_technique,is_emerging_as,tool_for_treatment_of_cancer
novel_technique,is_emerging_as,precise_tool_for_treatment_of_cancer
approaches,are,are_developed_for_treatment
novel_technique,Finally_is_emerging_as,precise_tool
novel_powerful_technique,is_emerging_as,tool_for_treatment
technique,is_emerging_as,precise_tool_for_targeted_treatment
powerful_technique,is_emerging_as,tool_for_targeted_treatment_of_cancer
novel_powerful_technique,is_emerging_as,precise_tool_for_treatment_of_cancer
technique,Finally_is_emerging_as,precise_tool_for_targeted_treatment
face-to-face_semi-structured_interview,was_conducted_with,12_purposively_sampled_women_with_sibling
face-to-face_semi-structured_interview,was_conducted_with,12_sampled_women
face-to-face_interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women
screening_mammography,are,However_underutilized
interview,was_conducted_with,12_sampled_women_with_female_sibling
interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women_with_sibling
face-to-face_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women
face-to-face_semi-structured_interview,was_conducted_by,approach_of_inquiry
semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women_with_sibling
face-to-face_interview,was_conducted_with,12_women_with_sibling
screening_behavior,are_important_factors,must_addressed_during_cancer_genetic_counseling_consultations
face-to-face_interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women
face-to-face_semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_female_sibling
interview,was,by_approach_conducted_with_12_women_with_female_sibling
interview,was,by_approach_conducted_with_12_women
interview,was,by_approach_conducted_with_12_sampled_women_with_female_sibling
face-to-face_semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women
semi-structured_interview,was,by_approach_conducted_with_12_purposively_sampled_women
screening_behavior,are_important_factors,must_addressed
understanding,will_aid_in,formulation_of_effective_management_plan
interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women_with_sibling
face-to-face_semi-structured_interview,was_conducted_with,12_sampled_women_with_sibling
face-to-face_semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women
semi-structured_interview,was,by_approach_conducted_with_12_sampled_women_with_female_sibling
cancer_risk_perception,are_important_factors,must_addressed
semi-structured_interview,was_conducted_with,12_women_with_sibling
interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_sibling
face-to-face_semi-structured_interview,was_conducted_with,12_purposively_sampled_women_with_female_sibling
face-to-face_interview,was_conducted_with,12_women_with_female_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_women_with_sibling
Overall_cancer_risk_perception,are_important_factors,must_addressed
Overall_cancer_risk_perception,are_factors,must_addressed_during_cancer_counseling_consultations
Transcripts,were,analyzed
face-to-face_semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_female_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_sibling
interview,was_conducted_by,phenomenological_approach
cancer_risk_perception,are_important_factors,must_addressed_during_cancer_counseling_consultations
face-to-face_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women
subjective_risk,is_shaped_by,their_beliefs_regarding_cancer_causation
face-to-face_interview,was,by_phenomenological_approach_conducted_with_12_sampled_women
understanding,will_aid_in,formulation_of_effective_management_plan_for_at-risk_women
Better_understanding,will_aid_in,formulation_of_management_plan_for_at-risk_women
face-to-face_interview,was,by_approach_of_inquiry_conducted_with_12_women_with_sibling
face-to-face_semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women_with_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_sampled_women_with_female_sibling
allotting,time_to,medical_consultation_fear
Better_understanding,will_aid_in,formulation_of_effective_management_plan_for_women
interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women
face-to-face_semi-structured_interview,was,by_approach_conducted_with_12_sampled_women_with_female_sibling
face-to-face_interview,was,by_approach_conducted_with_12_purposively_sampled_women_with_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women_with_female_sibling
face-to-face_semi-structured_interview,was,conducted
Filipino_women,incorporate,their_experiences
Guided,diagnosed_with,breast_cancer
face-to-face_interview,was_conducted_by,approach
face-to-face_interview,was,by_approach_conducted_with_12_sampled_women
semi-structured_interview,was_conducted_with,12_women
interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women
semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women_with_sibling
subjective_risk,is_also_shaped_by,their_beliefs_regarding_cancer_causation
Filipino_women,incorporate,their_experiences_living_with_sister
face-to-face_semi-structured_interview,was_conducted_with,12_purposively_sampled_women
interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women_with_sibling
face-to-face_semi-structured_interview,was_conducted_with,12_sampled_women_with_female_sibling
face-to-face_interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women_with_female_sibling
face-to-face_semi-structured_interview,was,by_approach_conducted_with_12_sampled_women_with_sibling
risk,is,shaped
interview,was_conducted_with,12_purposively_sampled_women_with_female_sibling
semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women_with_female_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_sampled_women_with_sibling
interview,was_conducted_by,phenomenological_approach_of_inquiry
interview,was,by_phenomenological_approach_conducted_with_12_women_with_female_sibling
face-to-face_semi-structured_interview,was_conducted_with,12_women_with_female_sibling
Overall_cancer_risk_perception,are_important_factors,must_addressed_during_cancer_genetic_counseling_consultations
face-to-face_semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_women_with_female_sibling
interview,was_conducted_with,12_women_with_sibling
Better_understanding,will_aid_in,formulation_of_effective_management_plan
semi-structured_interview,was_conducted_with,12_women_with_female_sibling
semi-structured_interview,was_conducted_with,12_sampled_women_with_female_sibling
semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women_with_female_sibling
interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_sibling
face-to-face_semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_women
face-to-face_semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_women
semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_women_with_sibling
semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_sampled_women
face-to-face_interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_sibling
Overall_cancer_risk_perception,are_important_factors,must_addressed_during_cancer_counseling_consultations
screening_behavior,are_factors,must_addressed
face-to-face_semi-structured_interview,was,by_approach_conducted_with_12_purposively_sampled_women
Better_understanding,will_aid_in,formulation_of_management_plan
interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women_with_female_sibling
Overall_cancer_risk_perception,are_factors,must_addressed_during_cancer_genetic_counseling_consultations
semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_sampled_women_with_female_sibling
interview,was,by_approach_conducted_with_12_purposively_sampled_women_with_sibling
screening_behavior,are_important_factors,must_addressed_during_cancer_counseling_consultations
face-to-face_interview,was_conducted_with,12_sampled_women
face-to-face_interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women
Transcripts,using,analysis
semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_women
interview,was,conducted
understanding,will_aid_in,formulation_of_management_plan_for_women
interview,was,by_approach_of_inquiry_conducted_with_12_women_with_sibling
face-to-face_semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women_with_female_sibling
study,sought,understand
semi-structured_interview,was_conducted_by,approach
semi-structured_interview,was_conducted_with,12_purposively_sampled_women_with_sibling
respondents,compare,themselves
12_sampled_women,is_with,female_sibling
semi-structured_interview,was,by_approach_conducted_with_12_women_with_female_sibling
face-to-face_interview,was_conducted_with,12_purposively_sampled_women_with_female_sibling
interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_female_sibling
semi-structured_interview,was,by_approach_conducted_with_12_women
face-to-face_interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women_with_sibling
interview,was_conducted_by,approach
face-to-face_semi-structured_interview,was,by_approach_conducted_with_12_purposively_sampled_women_with_sibling
semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_sibling
risk,is_shaped_by,their_beliefs_regarding_cancer_causation
face-to-face_interview,was,by_phenomenological_approach_conducted_with_12_women
face-to-face_semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women_with_female_sibling
semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women
cancer_risk_perception,are_factors,must_addressed
face-to-face_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women
face-to-face_interview,was,by_approach_conducted_with_12_women_with_female_sibling
interview,was,by_phenomenological_approach_conducted_with_12_sampled_women_with_sibling
interview,was,by_approach_of_inquiry_conducted_with_12_women
face-to-face_interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_female_sibling
face-to-face_interview,was_conducted_with,12_purposively_sampled_women
face-to-face_semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women
face-to-face_semi-structured_interview,was_conducted_by,phenomenological_approach
Overall_cancer_risk_perception,are_factors,must_addressed
semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women
risk,is,also_shaped
Filipino_women,incorporate,their_experiences_living
face-to-face_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women_with_sibling
semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_women_with_sibling
face-to-face_interview,was,by_phenomenological_approach_conducted_with_12_women_with_sibling
interview,was_conducted_with,12_purposively_sampled_women
semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women
interview,was,by_phenomenological_approach_conducted_with_12_sampled_women
face-to-face_semi-structured_interview,was,by_approach_conducted_with_12_women
semi-structured_interview,was,by_approach_conducted_with_12_purposively_sampled_women_with_female_sibling
face-to-face_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women_with_sibling
interview,was_conducted_by,approach_of_inquiry
interview,was,by_phenomenological_approach_conducted_with_12_women
face-to-face_semi-structured_interview,was,by_approach_conducted_with_12_purposively_sampled_women_with_female_sibling
subjective_risk,is,shaped
subjective_risk,is_shaped_by,their_beliefs
face-to-face_semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_women_with_female_sibling
semi-structured_interview,was,by_approach_conducted_with_12_sampled_women
subjective_risk,is,also_shaped
face-to-face_semi-structured_interview,was,by_approach_conducted_with_12_sampled_women
face-to-face_interview,was,by_approach_conducted_with_12_sampled_women_with_female_sibling
face-to-face_interview,was_conducted_by,phenomenological_approach_of_inquiry
interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women
face-to-face_semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_women_with_sibling
Better_understanding,will_aid_in,formulation_of_effective_management_plan_for_at-risk_women
cancer_risk_perception,are_factors,must_addressed_during_cancer_genetic_counseling_consultations
face-to-face_interview,was_conducted_with,12_sampled_women_with_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_sampled_women
Guided,diagnosed_before,age_50
face-to-face_interview,was_conducted_with,12_purposively_sampled_women_with_sibling
interview,was_conducted_with,12_sampled_women_with_sibling
face-to-face_semi-structured_interview,was_conducted_with,12_women
risk,is_also_shaped_by,their_beliefs
semi-structured_interview,was_conducted_by,approach_of_inquiry
semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_sibling
face-to-face_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_female_sibling
semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women_with_sibling
semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_women_with_female_sibling
interview,was_conducted_with,12_sampled_women
Better_understanding,will_aid_in,formulation_of_management_plan_for_women
face-to-face_interview,was,conducted
face-to-face_interview,was_conducted_with,12_women
face-to-face_semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women_with_female_sibling
semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_women_with_female_sibling
face-to-face_interview,was,by_approach_conducted_with_12_women_with_sibling
semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_female_sibling
allotting,time_to,consultation_fear
semi-structured_interview,was_conducted_with,12_sampled_women_with_sibling
semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women_with_female_sibling
face-to-face_interview,was,by_phenomenological_approach_conducted_with_12_sampled_women_with_female_sibling
semi-structured_interview,was_conducted_with,12_sampled_women
semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women_with_female_sibling
semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women
face-to-face_interview,was_conducted_by,approach_of_inquiry
screening_mammography,are,underutilized
understanding,will_aid_in,formulation
face-to-face_interview,was,by_phenomenological_approach_conducted_with_12_women_with_female_sibling
interview,was,by_approach_of_inquiry_conducted_with_12_women_with_female_sibling
face-to-face_interview,was,by_approach_conducted_with_12_sampled_women_with_sibling
interview,was,by_approach_conducted_with_12_purposively_sampled_women
interview,was,by_approach_conducted_with_12_sampled_women
face-to-face_interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women_with_sibling
face-to-face_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women
face-to-face_interview,was,by_approach_of_inquiry_conducted_with_12_women_with_female_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women_with_sibling
semi-structured_interview,was,by_approach_conducted_with_12_women_with_sibling
semi-structured_interview,was_conducted_by,phenomenological_approach_of_inquiry
Better_understanding,will_aid_in,formulation
face-to-face_interview,was,by_phenomenological_approach_conducted_with_12_sampled_women_with_sibling
interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women_with_female_sibling
face-to-face_semi-structured_interview,was_conducted_with,12_women_with_sibling
cancer_risk_perception,are_important_factors,must_addressed_during_cancer_genetic_counseling_consultations
face-to-face_interview,was_conducted_by,phenomenological_approach
interview,was_conducted_with,12_purposively_sampled_women_with_sibling
understanding,will_aid_in,formulation_of_management_plan_for_at-risk_women
semi-structured_interview,was_conducted_with,12_purposively_sampled_women_with_female_sibling
interview,was,by_approach_conducted_with_12_women_with_sibling
semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women_with_sibling
interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women_with_female_sibling
interview,was,by_phenomenological_approach_conducted_with_12_sampled_women_with_female_sibling
face-to-face_semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_sibling
experiences,come_with,breast_cancer_diagnosis
semi-structured_interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women
interview,was,by_approach_of_inquiry_conducted_with_12_purposively_sampled_women
interview,was,by_phenomenological_approach_conducted_with_12_women_with_sibling
interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women_with_female_sibling
study,Hence_sought,understand
face-to-face_interview,was,by_approach_conducted_with_12_purposively_sampled_women
breast_cancer_diagnosis,is_in,family_impact
cancer_risk_perception,are_factors,must_addressed_during_cancer_counseling_consultations
face-to-face_semi-structured_interview,was,by_approach_conducted_with_12_women_with_sibling
semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_female_sibling
screening_behavior,are_factors,must_addressed_during_cancer_genetic_counseling_consultations
interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women_with_sibling
face-to-face_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women_with_female_sibling
semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_sampled_women_with_sibling
semi-structured_interview,was,by_approach_conducted_with_12_sampled_women_with_sibling
semi-structured_interview,was,conducted
face-to-face_interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women_with_female_sibling
face-to-face_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_women_with_female_sibling
interview,was_conducted_with,12_women_with_female_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women
understanding,will_aid_in,formulation_of_effective_management_plan_for_women
face-to-face_semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women
face-to-face_semi-structured_interview,was_conducted_by,approach
risk,is_also_shaped_by,their_beliefs_regarding_cancer_causation
semi-structured_interview,was_conducted_by,phenomenological_approach
semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women
interview,was,by_approach_of_inquiry_conducted_with_12_sampled_women
interview,was_conducted_with,12_women
subjective_risk,is_also_shaped_by,their_beliefs
interview,was,by_approach_conducted_with_12_sampled_women_with_sibling
face-to-face_semi-structured_interview,was_conducted_by,phenomenological_approach_of_inquiry
face-to-face_interview,was,by_approach_conducted_with_12_purposively_sampled_women_with_female_sibling
risk,is_shaped_by,their_beliefs
face-to-face_interview,was_conducted_with,12_sampled_women_with_female_sibling
interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women
understanding,will_aid_in,formulation_of_management_plan
interview,was,by_approach_conducted_with_12_purposively_sampled_women_with_female_sibling
interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_purposively_sampled_women_with_female_sibling
Transcripts,using,thematic_analysis
semi-structured_interview,was_conducted_with,12_purposively_sampled_women
face-to-face_interview,was,by_approach_conducted_with_12_women
face-to-face_interview,was,by_approach_of_inquiry_conducted_with_12_women
semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_women
face-to-face_semi-structured_interview,was,by_phenomenological_approach_of_inquiry_conducted_with_12_sampled_women_with_sibling
screening_behavior,are_factors,must_addressed_during_cancer_counseling_consultations
face-to-face_semi-structured_interview,was,by_approach_conducted_with_12_women_with_female_sibling
face-to-face_semi-structured_interview,was,by_phenomenological_approach_conducted_with_12_purposively_sampled_women_with_sibling
semi-structured_interview,was,by_approach_conducted_with_12_purposively_sampled_women_with_sibling
Her_presentation,requiring,anti-HER2_therapy
we,Here_present,patient_with_relapsed_HER2
She,received,neoadjuvant_anti-HER2_treatment
we,present,elderly_patient
her_disease,relapsed_later_with,chest_wall_lesions
patient,importantly_had,one_year_without_deterioration
their_cardiotoxicities,used_concurrently_with,anthracyclines
Her_presentation,requiring,therapy
patient,had,one_year_without_deterioration
we,Here_present,patient
patient,importantly_had,one_year
patient,More_importantly_had,one_year_without_deterioration_in_her_ejection_fraction
patients,is_with,history_of_transtuzumab-induced_cardiac_dysfunction
we,Here_present,patient_with_HER2
elderly_patient,is_with,relapsed_HER2
she,received,five_doses
she,only_received,five_doses
We,treated_patient_with,lapatinib_combined
their_cardiotoxicities,used_with,anthracyclines
patient,had,one_year_of_disease_control
She,received_treatment_for,stage_III_breast_caner
Anti-HER2_therapies,have_changed,course_of_HER2_cancer
her_disease,relapsed_with,chest_wall_lesions
patient,More_importantly_had,one_year_without_deterioration
patient,had,one_year_of_disease_control_without_deterioration_in_her_ejection_fraction
We,discussed,management_of_HER2
her_disease,Unfortunately_relapsed_later_with,chest_wall_lesions
patient,had,one_year
patient,had,one_year_of_disease_control_without_deterioration
patient,More_importantly_had,one_year_of_disease_control
patient,importantly_had,one_year_without_deterioration_in_her_ejection_fraction
anti-HER2_therapy,is_in,patients_with_history_of_transtuzumab-induced_cardiac_dysfunction
their_cardiotoxicities,are,concerns
we,Here_present,elderly_patient_with_relapsed_HER2
Her_presentation,was_unusual_for,physical_finding
we,present,patient_with_relapsed_HER2
we,Here_present,elderly_patient
she,only_received,five_doses_of_adjuvant_transtuzumab
She,received,treatment
patient,More_importantly_had,one_year_of_disease_control_without_deterioration
patient,had,one_year_without_deterioration_in_her_ejection_fraction
Her_presentation,requiring,additional_therapy
Anti-HER2_therapies,have_changed,aggressive_course_of_HER2_cancer
their_cardiotoxicities,are,major_concerns
we,present,patient_with_HER2
Anti-HER2_therapies,have_changed,course
We,discussed,management
Her_presentation,was,unusual
deterioration,is_in,her_ejection_fraction
We,discussed_management_with,chest_wall_disease
patient,More_importantly_had,one_year
we,present,patient
We,discussed,management_of_recurrent_HER2
Her_presentation,requiring,additional_anti-HER2_therapy
patient,More_importantly_had,one_year_of_disease_control_without_deterioration_in_her_ejection_fraction
she,received,five_doses_of_adjuvant_transtuzumab
patient,importantly_had,one_year_of_disease_control_without_deterioration
patient,importantly_had,one_year_of_disease_control
She,received,anti-HER2_treatment
Her_presentation,was_unusual_for,finding
we,present,elderly_patient_with_relapsed_HER2
she,received,five_doses_of_transtuzumab
Anti-HER2_therapies,have_changed,aggressive_course
we,present,elderly_patient_with_HER2
She,received,neoadjuvant_treatment
she,only_received,five_doses_of_transtuzumab
We,treated_patient_with,lapatinib
We,treated,patient
patient,importantly_had,one_year_of_disease_control_without_deterioration_in_her_ejection_fraction
we,Here_present,elderly_patient_with_HER2
her_disease,Unfortunately_relapsed_with,chest_wall_lesions
TNBC,is_indicator_of,status
we,investigated,involved_in_cancer_development
TNBC,has,So_far_has_associated_with_mutations_in_BRCA1
TNBC,has,far_has_associated_with_mutations
12-15_%,are,triple-negative_breast_cancers
TNBC,has,So_far_has_mainly_associated
TNBC,has,has_mainly_associated_with_mutations
TNBC,is_additional_indicator_of,status
TNBC,has,has_associated_with_mutations
TNBC,is_indicator_of,mutational_status_besides_family_history
mutations,are_involved_in,cancer_development
TNBC,has,has_associated_with_mutations_in_BRCA1
TNBC,has,So_far_has_mainly_associated_with_mutations
TNBC,has,has_mainly_associated_with_mutations_in_BRCA1
TNBC,is_indicator_of,status_besides_family_history
mutations,is_in,BRCA1
we,Therefore_investigated,involved_in_cancer_development
mutations,are,involved
we,Therefore_investigated,involved
Breast_cancer,is,cancer
%,are,triple-negative_breast_cancers
TNBC,has,has_mainly_associated
repair,is,complex
Breast_cancer,is,common_cancer
TNBC,is,additional
Breast_cancer,is_cancer_in,women
12-15_%,are,breast_cancers
TNBC,is_additional_indicator_of,mutational_status
TNBC,has,far_has_mainly_associated_with_mutations_in_BRCA1
TNBC,is,indicator
TNBC,has,far_has_mainly_associated
common_cancer,is_in,women
Breast_cancer,is,most_common_cancer
we,investigated,involved
Breast_cancer,is_common_cancer_in,women
mutations,is_in,other_genes
TNBC,is_additional_indicator_of,mutational_status_besides_family_history
TNBC,has,So_far_has_associated_with_mutations
TNBC,has,far_has_associated
TNBC,has,far_has_mainly_associated_with_mutations
TNBC,is,additional_indicator
Breast_cancer,is_most_common_cancer_in,women
%,are,breast_cancers
TNBC,has,So_far_has_mainly_associated_with_mutations_in_BRCA1
TNBC,is_indicator_of,mutational_status
TNBC,has,So_far_has_associated
TNBC,has,far_has_associated_with_mutations_in_BRCA1
TNBC,has,has_associated
TNBC,is_additional_indicator_of,status_besides_family_history
identification,would,Thus_would_crucial
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker
we,Here_analyzed,23_studies
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_clinical_biomarker
low_cTn_levels,is_related_to,outcome_with_good_value
different_studies,are_necessary_as,biomarker_in_patients_with_breast_cancer
different_studies,are_necessary_as,biomarker
studies,are,still_necessary_for_adoption_as_routine_clinical_biomarker_in_patients
studies,are_necessary_In,conclusion
troponins,have,high_sensitivity
low_cTn_levels,is_related_to,better_outcome_with_good_value
we,analyzed,23_studies
studies,are,In_conclusion_still_necessary_as_routine_clinical_biomarker_in_patients_with_breast_cancer
cardiotoxicity_diagnosis,is_in,patients
studies,are,still_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients
different_studies,are,In_conclusion_still_necessary_for_adoption
studies,are,necessary_for_adoption_as_biomarker
Anthracyclines,are,agents
different_studies,are,In_conclusion_necessary_as_biomarker_in_patients
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients_with_breast_cancer
cTn_levels,is_related_to,outcome_with_negative_value
studies,are,In_conclusion_still_necessary_for_adoption_as_clinical_biomarker
use,has,has_applied_during_chemotherapy
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_in_combination
studies,are_still_necessary_as,clinical_biomarker_in_patients
studies,are,In_conclusion_necessary_for_adoption_as_clinical_biomarker_in_patients
studies,are,still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker
different_studies,are,In_conclusion_still_necessary_for_adoption_as_routine_clinical_biomarker_in_patients
different_studies,are,In_conclusion_still_necessary_for_adoption_as_clinical_biomarker_in_patients
studies,are,In_conclusion_necessary_for_adoption_as_routine_biomarker_in_patients
different_studies,are,still_necessary_for_adoption_of_cTn_as_clinical_biomarker
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_biomarker
different_studies,are,In_conclusion_still_necessary_for_adoption_as_routine_clinical_biomarker_in_patients_with_breast_cancer
studies,are,still_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_in_combination_mainly_with_trastuzumab
studies,are,still_necessary_for_adoption_as_clinical_biomarker_in_patients
low_cTn_levels,is_related_to,better_outcome_with_negative_value
different_studies,are,In_conclusion_necessary_for_adoption_as_routine_clinical_biomarker_in_patients
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis
different_studies,are,In_conclusion_still_necessary_as_clinical_biomarker_in_patients
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_alone_in_combination
studies,are,still_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated
studies,are_still_necessary_as,clinical_biomarker_in_patients_with_breast_cancer
different_studies,are_necessary_as,biomarker_in_patients
use,has,Therefore_has_applied
studies,are,In_conclusion_still_necessary_for_adoption_as_clinical_biomarker_in_patients
cTn_levels,is_related_to,better_outcome_with_good_negative_value
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_in_combination
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_alone_in_combination_with_trastuzumab
studies,are_still_necessary_for,adoption
different_studies,are,In_conclusion_necessary_for_adoption_as_routine_biomarker_in_patients
studies,are,In_conclusion_necessary_for_adoption_of_cTn
different_studies,are,still_necessary
studies,are_necessary_as,routine_biomarker_in_patients
different_studies,are,In_conclusion_necessary_for_adoption_as_routine_clinical_biomarker
different_studies,are,necessary_for_adoption_as_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,necessary_for_adoption_as_routine_biomarker
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_clinical_biomarker
cTn,is_in,preclinical_phase
studies,are,In_conclusion_necessary_as_clinical_biomarker_in_patients
studies,are,still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_necessary_for_adoption_as_biomarker_in_patients
different_studies,are_still_necessary_for,adoption_of_cTn
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_biomarker_in_patients_with_breast_cancer
low_cTn_levels,is_related_to,better_outcome_with_negative_predictive_value
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_in_combination
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients_with_breast_cancer
studies,are,still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients
studies,are,In_conclusion_still_necessary_for_adoption_as_biomarker_in_patients
different_studies,are,necessary_for_adoption_of_cTn_as_biomarker_in_patients
identification,would,would_crucial
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients
different_studies,are,In_conclusion_necessary_as_routine_biomarker
studies,are,necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_biomarker
different_studies,are,still_necessary_for_adoption_of_cTn_as_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_necessary_as_biomarker
studies,are_still_necessary_as,routine_clinical_biomarker_in_patients
low_cTn_levels,is_related_to,outcome
different_studies,are_necessary_as,clinical_biomarker_in_patients
use,has,has_applied_to_identification_evaluation
low_cTn_levels,is_related_to,outcome_with_negative_predictive_value
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_in_combination
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_in_combination_with_trastuzumab
studies,are,In_conclusion_still_necessary_as_clinical_biomarker_in_patients_with_breast_cancer
association,contribute_to,diagnosis_of_cardiotoxicity
Cardiac_troponins,have,sensitivity
studies,are,In_conclusion_still_necessary_for_adoption
different_studies,are_still_necessary_for,adoption
studies,are,In_conclusion_necessary_as_biomarker_in_patients_with_breast_cancer
studies,are,still_necessary_for_adoption_of_cTn_as_biomarker
different_studies,are,still_necessary_for_adoption_as_clinical_biomarker_in_patients
studies,are,In_conclusion_necessary_for_adoption_as_routine_clinical_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_necessary_as_clinical_biomarker_in_patients_with_breast_cancer
association,contribute_to,early_diagnosis
troponins,are_used_in,diagnosis_of_acute_coronary_syndromes
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_biomarker
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_biomarker_in_patients
use,has,Therefore_has_applied_to_early_identification_evaluation
different_studies,are_necessary_as,routine_biomarker_in_patients
different_studies,are,In_conclusion_still_necessary_as_routine_clinical_biomarker_in_patients_with_breast_cancer
Cardiac_troponins,are,used
different_studies,are,still_necessary_for_adoption_as_routine_clinical_biomarker_in_patients
studies,are,necessary_for_adoption_of_cTn_as_biomarker
different_studies,are,In_conclusion_still_necessary_for_adoption_as_clinical_biomarker
different_studies,are,still_necessary_for_adoption_as_routine_clinical_biomarker
studies,are,necessary_for_adoption_as_biomarker_in_patients
Anthracyclines,are,agents_used_in_breast_cancer_treatment
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_in_combination_with_trastuzumab
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_biomarker_in_patients
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses
studies,are,necessary_for_adoption_of_cTn_as_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_still_necessary_for_adoption_as_routine_biomarker
different_studies,are,In_conclusion_necessary_as_clinical_biomarker
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_in_combination_mainly_with_trastuzumab
studies,are_still_necessary_as,routine_biomarker_in_patients_with_breast_cancer
use,has,has_applied_to_early_identification_evaluation
different_studies,are_necessary_as,routine_clinical_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_necessary_as_routine_biomarker_in_patients
troponins,have_sensitivity_in,injury
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_in_combination_mainly_with_trastuzumab
studies,are,necessary_for_adoption_of_cTn_as_biomarker_in_patients
we,analyzed,23_cross-sectional_prospective_studies
different_studies,are,In_conclusion_necessary_for_adoption_as_routine_clinical_biomarker_in_patients_with_breast_cancer
studies,are_necessary_as,biomarker_in_patients
troponins,have_sensitivity_in,myocardial_injury
cTn_levels,is_related_to,outcome_with_good_negative_predictive_value
studies,are_still_necessary_for,adoption_of_cTn
studies,are,In_conclusion_necessary_for_adoption_as_routine_biomarker
Anthracyclines,are,most_common_agents_used
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients_with_breast_cancer
studies,are,still_necessary_for_adoption_as_routine_clinical_biomarker
studies,are_still_necessary_as,routine_clinical_biomarker
different_studies,are,necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients
low_cTn_levels,is_related_to,better_outcome_with_predictive_value
different_studies,are_necessary_as,routine_biomarker_in_patients_with_breast_cancer
different_studies,are_still_necessary_as,clinical_biomarker_in_patients
identification,would,Thus_would_crucial_for_application_of_strategies
low_cTn_levels,is,related
studies,are,necessary_for_adoption_as_clinical_biomarker
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients
different_studies,are,In_conclusion_necessary_as_clinical_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_still_necessary_for_adoption_as_biomarker
studies,are,necessary_for_adoption_as_routine_biomarker
cTn_levels,is_related_to,better_outcome_with_predictive_value
studies,are,In_conclusion_still_necessary_as_clinical_biomarker
use,has,has_applied_to_early_identification_evaluation_during_chemotherapy
studies,are,still_necessary_for_adoption_of_cTn_as_biomarker_in_patients
different_studies,are,In_conclusion_necessary_for_adoption_as_clinical_biomarker
different_studies,are,still_necessary_for_adoption_of_cTn_as_routine_biomarker
studies,are,In_conclusion_necessary_as_routine_biomarker_in_patients_with_breast_cancer
studies,are_necessary_as,clinical_biomarker_in_patients_with_breast_cancer
studies,are,still_necessary_for_adoption_of_cTn_as_biomarker_in_patients_with_breast_cancer
different_studies,are,still_necessary_for_adoption_as_biomarker
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_alone_in_combination_with_trastuzumab
cTn_levels,is_related_to,outcome_with_good_value
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_biomarker
cTn_levels,is_related_to,better_outcome_with_good_negative_predictive_value
studies,are,still_necessary_for_adoption_as_biomarker
different_studies,are,necessary_for_adoption_as_biomarker_in_patients_with_breast_cancer
use,has,Therefore_has_applied_to_identification_evaluation_during_chemotherapy
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients
different_studies,are_still_necessary_as,clinical_biomarker_in_patients_with_breast_cancer
Cardiac_troponins,are_used_in,diagnosis_of_coronary_syndromes
low_cTn_levels,is_related_to,outcome_with_predictive_value
studies,are,still_necessary_for_adoption_as_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_biomarker
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_still_necessary_as_clinical_biomarker_in_patients
studies,are,still_necessary_for_adoption_as_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_biomarker_in_patients
different_studies,are,In_conclusion_still_necessary_as_clinical_biomarker_in_patients_with_breast_cancer
studies,are,still_necessary_for_adoption_as_clinical_biomarker
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients
we,Here_analyzed,23_prospective_studies
cTn_levels,is_related_to,better_outcome_with_value
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients_with_breast_cancer
different_studies,are,necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients_with_breast_cancer
low_cTn_levels,is_related_to,better_outcome_with_good_negative_predictive_value
different_studies,are_necessary_as,routine_clinical_biomarker
studies,are,In_conclusion_still_necessary_for_adoption_as_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines
different_studies,are,necessary_for_adoption_as_routine_clinical_biomarker_in_patients_with_breast_cancer
studies,are,necessary_for_adoption_as_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_clinical_biomarker
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_biomarker
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are_necessary_as,clinical_biomarker_in_patients_with_breast_cancer
Anthracyclines,are,most_common_agents_used_in_breast_cancer_treatment
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_in_combination_mainly_with_trastuzumab
studies,are_still_necessary_as,routine_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are_necessary_as,clinical_biomarker
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_in_combination
studies,are,In_conclusion_still_necessary_as_routine_clinical_biomarker
studies,are,necessary_for_adoption_as_routine_biomarker_in_patients
studies,are,necessary_for_adoption_as_routine_clinical_biomarker
different_studies,are,In_conclusion_necessary_for_adoption_as_clinical_biomarker_in_patients
use,has,Therefore_has_applied_during_chemotherapy
different_studies,are,necessary_for_adoption_of_cTn_as_biomarker
cTn_levels,is_related_to,outcome
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated
studies,are,In_conclusion_necessary_as_routine_clinical_biomarker_in_patients
different_studies,are,necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients
different_studies,are,In_conclusion_necessary_as_biomarker_in_patients_with_breast_cancer
studies,are,necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_alone_in_combination_with_trastuzumab
cTn_levels,is_related_to,outcome_with_predictive_value
studies,are,still_necessary_for_adoption_as_routine_biomarker_in_patients
direct_relationship,is_with,accumulated_dose_of_treatment
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_alone
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients_with_breast_cancer
cTn_levels,is_related_to,outcome_with_negative_predictive_value
low_cTn_levels,is_related_to,outcome_with_value
use,has,Therefore_has_applied_to_identification_evaluation
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients
different_studies,are,still_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients_with_breast_cancer
better_outcome,is_with,good_negative_predictive_value
studies,are,In_conclusion_necessary_as_routine_clinical_biomarker
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_biomarker_in_patients
different_studies,are,In_conclusion_necessary_as_routine_biomarker_in_patients
different_studies,are,still_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients
different_studies,are,In_conclusion_necessary_for_adoption_as_clinical_biomarker_in_patients_with_breast_cancer
troponins,are_used_in,diagnosis_of_syndromes
different_studies,are_still_necessary_as,biomarker_in_patients_with_breast_cancer
different_studies,are,necessary_for_adoption_of_cTn_as_routine_clinical_biomarker
different_studies,are,still_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn
Cardiac_troponins,have_sensitivity_in,myocardial_injury
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_in_combination_mainly_with_trastuzumab
studies,are,necessary_for_adoption_as_routine_clinical_biomarker_in_patients
different_studies,are,In_conclusion_still_necessary_for_adoption_as_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_still_necessary_for_adoption_as_routine_clinical_biomarker_in_patients_with_breast_cancer
low_cTn_levels,is_related_to,better_outcome_with_good_predictive_value
different_studies,are,still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker
studies,are_still_necessary_as,routine_biomarker
Anthracyclines,are,agents_used
low_cTn_levels,is_related_to,outcome_with_good_negative_predictive_value
studies,are,still_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients
studies,are_necessary_as,clinical_biomarker_in_patients
Cardiac_troponins,have_sensitivity_in,injury
studies,are,In_conclusion_still_necessary_as_routine_biomarker
cTn_levels,is_related_to,outcome_with_value
studies,are,still_necessary_for_adoption_as_routine_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients
studies,are,necessary_for_adoption_as_clinical_biomarker_in_patients
studies,are,In_conclusion_still_necessary_for_adoption_as_routine_clinical_biomarker
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients
different_studies,are,necessary_for_adoption_as_routine_clinical_biomarker_in_patients
studies,are,still_necessary_for_adoption_of_cTn_as_routine_biomarker
studies,are,In_conclusion_necessary_as_routine_biomarker
cTn_levels,is_related_to,better_outcome_with_negative_predictive_value
doses,is_in,combination_mainly_with_trastuzumab
studies,are,In_conclusion_still_necessary_for_adoption_as_biomarker
clinical_studies,is_in,cardiotoxicity_diagnosis
low_cTn_levels,is_related_to,outcome_with_good_negative_value
use,has,Therefore_has_applied_to_early_identification_evaluation_during_chemotherapy
troponins,are_used_in,diagnosis_of_coronary_syndromes
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_in_combination_mainly_with_trastuzumab
different_studies,are_still_necessary_as,biomarker
studies,are,In_conclusion_necessary_as_clinical_biomarker
different_studies,are,In_conclusion_still_necessary_as_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_in_combination_with_trastuzumab
different_studies,are,still_necessary_for_adoption_of_cTn_as_biomarker_in_patients
we,Here_analyzed,23_cross-sectional_prospective_studies
different_studies,are,necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients_with_breast_cancer
low_cTn_levels,is_related_to,outcome_with_negative_value
different_studies,are_necessary_In,conclusion
different_studies,are_still_necessary_as,routine_clinical_biomarker
studies,are,necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_in_combination_mainly_with_trastuzumab
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines
studies,are,In_conclusion_still_necessary_as_routine_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_still_necessary_as_routine_clinical_biomarker_in_patients
studies,are,necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients
studies,are_necessary_for,adoption_of_cTn
Cardiac_troponins,are_used_in,diagnosis_of_syndromes
different_studies,are_still_necessary_as,biomarker_in_patients
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker
studies,are,necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients_with_breast_cancer
troponins,are,used
studies,are,In_conclusion_still_necessary_as_biomarker_in_patients
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients
different_studies,are_necessary_for,adoption
low_cTn_levels,is_related_to,better_outcome_with_good_negative_value
different_studies,are,In_conclusion_still_necessary_as_clinical_biomarker
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_in_combination_with_trastuzumab
studies,are_still_necessary_as,routine_biomarker_in_patients
different_studies,are,necessary_for_adoption_as_routine_biomarker_in_patients_with_breast_cancer
association,is_with,different_biomarkers
different_studies,are,In_conclusion_necessary_for_adoption
studies,are,In_conclusion_necessary_for_adoption
studies,are,necessary_for_adoption_as_routine_biomarker_in_patients_with_breast_cancer
different_studies,are,necessary_for_adoption_of_cTn_as_routine_biomarker
studies,are,In_conclusion_still_necessary_for_adoption_as_routine_clinical_biomarker_in_patients
risk,has_remained,similar
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses
different_studies,are,necessary_for_adoption_as_routine_biomarker_in_patients
different_studies,are,In_conclusion_necessary_for_adoption_as_biomarker
different_studies,are,necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_still_necessary_as_routine_biomarker
studies,are,necessary_for_adoption_of_cTn_as_clinical_biomarker
different_studies,are,In_conclusion_necessary_for_adoption_as_routine_biomarker
different_studies,are,still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients
low_cTn_levels,is_related_to,outcome_with_good_predictive_value
identification,would,Thus_would_crucial_for_application
studies,are,still_necessary_for_adoption_as_biomarker_in_patients
Anthracyclines,are,common_agents
studies,are_still_necessary_as,clinical_biomarker
studies,are_necessary_as,routine_clinical_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines
association,contribute_to,early_diagnosis_of_cardiotoxicity
studies,are_necessary_as,routine_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker
different_studies,are,In_conclusion_still_necessary_as_routine_biomarker_in_patients
studies,are,In_conclusion_necessary_for_adoption_as_biomarker
studies,are_necessary_as,routine_biomarker
different_studies,are,In_conclusion_still_necessary_as_routine_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_alone
patients,is_with,breast_cancer
different_studies,are,necessary
different_studies,are,In_conclusion_still_necessary_for_adoption_as_routine_biomarker_in_patients
studies,are_still_necessary_In,conclusion
different_studies,are,In_conclusion_still_necessary_as_biomarker
cTn_levels,is_related_to,better_outcome_with_good_value
troponins,have,sensitivity
low_cTn_levels,is_related_to,better_outcome
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_still_necessary_as_biomarker_in_patients_with_breast_cancer
identification,would,would_crucial_for_application_of_strategies
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_alone_in_combination_mainly_with_trastuzumab
different_studies,are,necessary_for_adoption_as_clinical_biomarker_in_patients
studies,are,In_conclusion_necessary_for_adoption_as_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_still_necessary_for_adoption_as_clinical_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_in_combination_mainly_with_trastuzumab
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_alone
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_in_combination_with_trastuzumab
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_in_combination_with_trastuzumab
studies,are,necessary_for_adoption_of_cTn_as_routine_biomarker
different_studies,are,still_necessary_for_adoption_as_biomarker_in_patients
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis
Cardiac_troponins,are_used_in,diagnosis
different_studies,are,necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients
biomarker,is_in,patients_with_breast_cancer_receiving_with_anthracyclines
different_studies,are_still_necessary_as,routine_biomarker
different_studies,are,In_conclusion_necessary_for_adoption_as_routine_biomarker_in_patients_with_breast_cancer
studies,are_necessary_for,adoption
Anthracyclines,are,common_agents_used
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses
studies,are_still_necessary_as,biomarker_in_patients
cTn,have,have_validated_by_studies
different_studies,are,necessary_for_adoption_as_routine_clinical_biomarker
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_necessary_as_routine_biomarker_in_patients_with_breast_cancer
Anthracyclines,are,most_common_agents
troponins,are_used_in,diagnosis
different_studies,are,still_necessary_for_adoption_as_routine_biomarker
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_biomarker_in_patients_with_breast_cancer
studies,are_still_necessary_as,biomarker
studies,are_necessary_as,clinical_biomarker
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_biomarker
different_studies,are,In_conclusion_necessary_for_adoption_as_biomarker_in_patients
different_studies,are,In_conclusion_necessary_as_biomarker
Anthracyclines,are,common_agents_used_in_breast_cancer_treatment
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_alone_in_combination_mainly_with_trastuzumab
studies,are_still_necessary_as,biomarker_in_patients_with_breast_cancer
different_studies,are_still_necessary_In,conclusion
cTn_levels,is_related_to,outcome_with_good_negative_value
studies,are,In_conclusion_still_necessary_as_routine_biomarker_in_patients
different_studies,are_still_necessary_as,routine_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_still_necessary_as_routine_clinical_biomarker
Cardiac_troponins,are_used_in,diagnosis_of_acute_coronary_syndromes
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_alone
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_alone_in_combination
different_studies,are,In_conclusion_necessary_as_clinical_biomarker_in_patients
we,analyzed,23_prospective_studies
studies,are,In_conclusion_necessary_for_adoption_as_routine_biomarker_in_patients_with_breast_cancer
different_studies,are,necessary_for_adoption_of_cTn_as_clinical_biomarker
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_biomarker
studies,are,necessary_for_adoption_as_clinical_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_in_combination_with_trastuzumab
different_studies,are_necessary_as,routine_clinical_biomarker_in_patients
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_in_combination
association,contribute_to,diagnosis
different_studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_necessary_for_adoption_as_biomarker_in_patients_with_breast_cancer
different_studies,are_necessary_as,routine_biomarker
different_studies,are,still_necessary_for_adoption_as_clinical_biomarker
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_alone_in_combination
different_studies,are_necessary_for,adoption_of_cTn
studies,are,In_conclusion_necessary_as_routine_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_still_necessary_for_adoption_as_routine_biomarker_in_patients_with_breast_cancer
studies,are,still_necessary_for_adoption_of_cTn_as_clinical_biomarker
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_alone_in_combination_with_trastuzumab
Cardiac_troponins,are_used_in,diagnosis_of_acute_syndromes
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_in_combination
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_alone_in_combination
studies,are,In_conclusion_necessary_for_adoption_as_clinical_biomarker_in_patients_with_breast_cancer
troponins,are_used_in,diagnosis_of_acute_syndromes
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_in_combination
studies,are,still_necessary
identification,would,would_crucial_for_application
different_studies,are_still_necessary_as,routine_biomarker_in_patients
studies,are,In_conclusion_necessary_for_adoption_as_clinical_biomarker
low_cTn_levels,is_related_to,better_outcome_with_value
studies,are,In_conclusion_necessary_for_adoption_as_routine_clinical_biomarker_in_patients
use,has,has_applied
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated
different_studies,are_still_necessary_as,routine_clinical_biomarker_in_patients
different_studies,are,still_necessary_for_adoption_as_biomarker_in_patients_with_breast_cancer
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_alone_in_combination_mainly_with_trastuzumab
studies,are,still_necessary_for_adoption_as_routine_biomarker_in_patients_with_breast_cancer
cTn_levels,is_related_to,better_outcome_with_good_predictive_value
different_studies,are,necessary_for_adoption_of_cTn_as_biomarker_in_patients_with_breast_cancer
different_studies,are,still_necessary_for_adoption_as_clinical_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients
studies,are,In_conclusion_still_necessary_for_adoption_as_clinical_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients
studies,are,necessary_for_adoption_as_routine_clinical_biomarker_in_patients_with_breast_cancer
cTn_levels,is_related_to,better_outcome
different_studies,are,In_conclusion_still_necessary_for_adoption_as_biomarker_in_patients
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines
different_studies,are,In_conclusion_still_necessary_as_biomarker_in_patients
cTn,have,have_validated_by_clinical_studies
studies,are,In_conclusion_still_necessary_as_biomarker
different_studies,are,still_necessary_for_adoption_as_routine_biomarker_in_patients
Cardiac_troponins,have,high_sensitivity
cTn_levels,is_related_to,outcome_with_good_predictive_value
studies,are_necessary_as,biomarker
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn_as_clinical_biomarker
different_studies,are,still_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are_still_necessary_as,clinical_biomarker
studies,are,necessary
cTn_levels,is_related_to,better_outcome_with_negative_value
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_doses_of_anthracyclines_in_combination_with_trastuzumab
identification,would,Thus_would_crucial_for_application_of_preventive_strategies
studies,are_necessary_as,routine_clinical_biomarker
studies,are,In_conclusion_still_necessary_for_adoption_of_cTn_as_clinical_biomarker_in_patients
routine_clinical_biomarker,is_in,patients_with_breast_cancer_receiving
different_studies,are,necessary_for_adoption_as_clinical_biomarker
different_studies,are,still_necessary_for_adoption_as_routine_biomarker_in_patients_with_breast_cancer
combination,is_with,mainly_trastuzumab
different_studies,are,still_necessary_for_adoption_as_routine_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_necessary_as_routine_clinical_biomarker_in_patients_with_breast_cancer
studies,are,In_conclusion_necessary_for_adoption_as_routine_clinical_biomarker
different_studies,are,In_conclusion_necessary_as_routine_clinical_biomarker
studies,are,necessary_for_adoption_of_cTn_as_routine_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_still_necessary_for_adoption_as_routine_clinical_biomarker
different_studies,are,still_necessary_for_adoption_of_cTn_as_routine_clinical_biomarker_in_patients_with_breast_cancer
different_studies,are,In_conclusion_necessary_as_routine_clinical_biomarker_in_patients
studies,are,In_conclusion_still_necessary_for_adoption_as_routine_biomarker_in_patients_with_breast_cancer
different_studies,are,necessary_for_adoption_as_biomarker_in_patients
different_studies,are,still_necessary_for_adoption_of_cTn_as_biomarker
studies,are,In_conclusion_necessary_as_biomarker_in_patients
studies,are,still_necessary_for_adoption_as_routine_biomarker
risk,however_has_remained,similar
cTn,have,have_validated_by_clinical_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses
identification,would,would_crucial_for_application_of_preventive_strategies
cTn,have,have_validated_by_studies_in_cardiotoxicity_diagnosis_in_patients_treated_with_high_doses_of_anthracyclines_alone_in_combination_mainly_with_trastuzumab
cTn_levels,is,related
use,has,has_applied_to_identification_evaluation_during_chemotherapy
studies,are,In_conclusion_still_necessary_for_adoption_as_routine_biomarker_in_patients
different_studies,are_still_necessary_as,routine_biomarker_in_patients_with_breast_cancer
we,Here_analyzed,23_cross-sectional_studies
different_studies,are,necessary_for_adoption_as_biomarker
different_studies,are,In_conclusion_still_necessary_for_adoption_as_routine_biomarker
studies,are,In_conclusion_still_necessary_as_routine_clinical_biomarker_in_patients
studies,are,necessary_for_adoption_of_cTn_as_routine_clinical_biomarker
we,analyzed,23_cross-sectional_studies
different_studies,are,In_conclusion_necessary_for_adoption_of_cTn
studies,are_necessary_as,biomarker_in_patients_with_breast_cancer
studies,are_necessary_as,routine_clinical_biomarker_in_patients
most,was_due_to,type
aim,provide,update_on_risk_factors
RESULTS,met_In,total_581_patients
most,was_due_to,type_of_surgery_of_surgery
Seroma_formation,was,measured
72_patients,received,NAC
IORT,received,NAC
seroma_production,is_in,primary_breast_cancer_patients_treated_between_01.01.2010
seroma_production,amount_of_was,82.5_ml
update,considering,treatment_options
IORT,explained,amount_of_observed_variation_in_seroma_production
IORT,explained,amount_of_observed_variation
seroma_production,Median_amount_of_was,82.5_ml
IORT,explained,amount_of_variation
Seroma_formation,using,wound_drains_placed_in_breast
aim,provide,update_on_risk_factors_for_seroma_production
aim,provide,update
retrospective_analysis,was,performed
patients,had,30.1_%
IORT,explained,amount
Median_amount,was,82.5_ml
radical_surgical_approaches,is_in,breast_cancer
IORT,explained,amount_of_variation_in_seroma_production
update,considering,latest_treatment_options
age,was,60_years
patients,received,NAC
analysis,was,performed
Median_age,was,60_years
most,was_due_to,type_of_surgery
Seroma_formation,using,wound_drains
observed_variation,is_in,seroma_production
aim,provide,update_on_risk_factors_for_seroma_production_after_breast_cancer_surgery
Patients,is_with,previous_breast/axillary_surgery
amount,was,82.5_ml
Seroma_formation,using,wound_drains_placed
most,was,due
analysis,is_done_by,algorithm
Mammography,is_most_effective_techniqueused_for,detection_of_breast_cancer_in_women
Mammography,is_most_effective_techniqueused_for,detection_of_breast_cancer
images,using,neural_network_classifier
Breast_Cancer,is_most_invasive_disease_next_to,lung_cancer
Breast_Cancer,is_disease_next_to,lung_cancer_in_human
towavelet_filter_Shearlet_coefficients,are_sensitive,directional
Mammography,is_effective_and_efficient_techniqueused_for,detection_of_breast_cancer_in_women
Similar_towavelet_filter_Shearlet_coefficients,are_sensitive,directional
Mammography,is_techniqueused_for,detection
Mammography,is_techniqueused_for,detection_in_women
result,generate,malign
detectionof_breast_cancer,is,accomplished
analysis,is,done
Breast_Cancer,is,invasive_disease
Similar_towavelet_filter_Shearlet_coefficients,are,sensitive
the,may,may_misdiagnosis
Mammography,is_most_effective_and_efficient_techniqueused_for,detection_of_breast_cancer_in_women
paper,aid_radiologist_to,diagnosis_breast_cancer
Mammography,is,effective_techniqueused
Mammography,is_effective_techniqueused_for,detection_of_breast_cancer_in_women
Mammography,is_most_effective_and_efficient_techniqueused_for,detection
Mammography,is_effective_and_efficient_techniqueused_for,detection_of_breast_cancer
the_resulting,may,may_misdiagnosis
Mammography,is_most_effective_and_efficient_techniqueused_for,detection_in_women
Mammography,is_most_effective_and_efficient_techniqueused_for,detection_of_breast_cancer
towavelet_filter_Shearlet_coefficients,are_sensitive,more_directional
Mammography,is,techniqueused
Mammography,is_most_effective_techniqueused_for,detection_in_women
Shearlet,transform,image_enhancement_method
Breast_Cancer,is_invasive_disease_next_to,lung_cancer_in_human
Mammography,is_effective_techniqueused_for,detection_in_women
Many_features,are,extracted
multiresolution_result,generate,benign
mammographic_images,using,neural_network_classifier
Similar_towavelet_filter_Shearlet_coefficients,are_sensitive,more_directional
towavelet_filter_Shearlet_coefficients,are,sensitive
lung_cancer,is_in,human
Mammography,is_effective_techniqueused_for,detection
mammographic_images,using,network_classifier
images,using,network_classifier
Mammography,is_effective_and_efficient_techniqueused_for,detection
Mammography,is_most_effective_techniqueused_for,detection
Breast_Cancer,is_most_invasive_disease_next_to,lung_cancer_in_human
Breast_Cancer,is_disease_next_to,lung_cancer
multiresolution_result,generate,malign
Mammography,improve,breast_cancer_prognosis
Breast_Cancer,is,most_invasive_disease
Mammography,is,most_effective_techniqueused
Mammography,is_techniqueused_for,detection_of_breast_cancer_in_women
result,generate,benign
breast_cancer,is,accomplished
features,are,extracted
Mammography,is_effective_techniqueused_for,detection_of_breast_cancer
Breast_Cancer,is,disease
Breast_Cancer,is_invasive_disease_next_to,lung_cancer
Diagnosis,is,implemented
Mammography,also_improve,breast_cancer_prognosis
detectionof_breast_cancer,is_accomplished_by,X-ray_mammography
Mammography,is_techniqueused_for,detection_of_breast_cancer
detection,is_in,women
Mammography,is_effective_and_efficient_techniqueused_for,detection_in_women
breast_cancer,is_accomplished_by,X-ray_mammography
paper,aid,radiologist
analysis,is_done_by,suitable_algorithm
concept,is_very_appealing_given,its_accuracy_coupled_with_possibility_of_reduction_in_cost
concept,Therefore_is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility
concept,is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
larger_studies,are,necessary_results
patient,as,outcome_over_costs
larger_prospective_studies,are_initial_results_with,MRI_protocols
it,is,Hence_currently_only_routinely_implemented_in_screening_at_risk_of_breast_cancer
concept,is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction
concept,is_appealing_given,its_high_diagnostic_accuracy_coupled
costs,However_limit,its_use
it,is_currently_only_routinely_implemented_in,screening
concept,Therefore_is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
concept,is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction_in_cost
concept,Therefore_is_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
time,limit,its_use
it,Hence_is_routinely_implemented_at,increased_risk
concept,is_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
larger_prospective_studies,are,necessary_initial_results
it,is,Hence_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
breast,MRI_of_is,most_sensitive_test
it,is,Hence_currently_implemented_in_screening_at_risk_of_breast_cancer
article,give,overview_of_abbreviated_breast_MRI_protocols
Healthcare_policy_makers,curbing_use,continuing
their_emerging_role,is_in,new_value-based_healthcare_paradigm
it,is,Hence_currently_only_routinely_implemented_in_screening_at_increased_risk_of_breast_cancer
concept,is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction
high_costs,However_limit,its_widespread_use
long_time,limit,its_use
prospective_studies,are_necessary_results_with,abbreviated_MRI_protocols
it,is,currently_routinely_implemented_in_screening_at_risk_of_breast_cancer
it,is_routinely_implemented_in,screening_of_women
it,Hence_is_currently_routinely_implemented_at,risk
larger_studies,are_results_with,abbreviated_MRI_protocols
studies,are,initial_results
studies,are,necessary_initial_results
concept,Therefore_is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
it,is,only_routinely_implemented_in_screening_at_risk_of_breast_cancer
concept,is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
concept,Therefore_is_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
concept,Therefore_is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction
it,is,currently_routinely_implemented_in_screening_at_increased_risk_of_breast_cancer
concept,is_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
it,is,currently_routinely_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
concept,Therefore_is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
limitations,abbreviated,dynamic_contrast-enhanced
it,is_only_routinely_implemented_in,screening_of_women
it,is,implemented_in_screening_at_risk
Healthcare_policy_makers,curbing,use
it,is,Hence_implemented
concept,Therefore_is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility
Healthcare_policy_makers,curbing,use_of_imaging_examinations
Healthcare_policy_makers,curbing,use_of_advanced_imaging_examinations
it,Hence_is_currently_implemented_in,screening
long_time,However_limit,its_use
it,is,Hence_currently_only_routinely_implemented_in_screening_at_increased_risk
it,is,Hence_only_routinely_implemented_in_screening_of_women_at_increased_risk
it,is_routinely_implemented_at,risk
concept,Therefore_is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
concept,Therefore_is_appealing_given,its_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
concept,is,Therefore_very_appealing
it,Hence_is_only_routinely_implemented_at,increased_risk_of_breast_cancer
concept,Therefore_is_very_appealing_given,its_high_diagnostic_accuracy_coupled
it,Hence_is_implemented_at,risk_of_breast_cancer
larger_prospective_studies,are,necessary_results
concept,Therefore_is_very_appealing_given,its_high_accuracy
long_scan_time,However_limit,its_widespread_use
concept,is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost
it,is_routinely_implemented_at,increased_risk_of_breast_cancer
it,is,only_routinely_implemented_in_screening_at_risk
it,is,Hence_implemented_in_screening_of_women_at_increased_risk
concept,Therefore_is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction
it,is_currently_only_routinely_implemented_at,increased_risk
concept,is_very_appealing_given,its_high_accuracy
it,is,Hence_only_routinely_implemented
prospective_studies,are,necessary_initial_results
concept,Therefore_is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost
it,is,only_routinely_implemented
concept,Therefore_is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost
it,is_currently_implemented_at,risk_of_breast_cancer
it,is_currently_routinely_implemented_at,risk
MRI,is_test_for,breast_cancer_detection
scan_time,However_limit,its_use
MRI,is,sensitive_test
larger_studies,are,results
it,is,Hence_currently_only_routinely_implemented_in_screening_of_women_at_risk_of_breast_cancer
concept,is_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
it,is_currently_implemented_at,increased_risk
concept,is_appealing_given,its_high_accuracy
it,is,Hence_routinely_implemented_in_screening_at_risk_of_breast_cancer
concept,is_appealing_given,its_accuracy_coupled_with_possibility
it,is_routinely_implemented_at,increased_risk
concept,Therefore_is_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction
MRI,outperforms_imaging_with,mammography_digital_breast_tomosynthesis
concept,is_very_appealing_given,its_accuracy
concept,Therefore_is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility
concept,is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
larger_prospective_studies,are_necessary_results_with,MRI_protocols
MRI,outperforms,conventional_imaging
it,is,currently_implemented_in_screening_at_risk
concept,is_appealing_given,its_high_diagnostic_accuracy
concept,is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost
concept,is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction
it,is,only_routinely_implemented_in_screening_of_women_at_increased_risk
larger_prospective_studies,are_results_with,abbreviated_MRI_protocols
recent_concerns,are,are_investigated_for_breast_cancer_diagnosis
concept,Therefore_is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction
long_scan_time,However_limit,its_use
it,is,implemented_in_screening_at_risk_of_breast_cancer
it,Hence_is_currently_implemented_in,screening_of_women
concept,is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction
concept,is_appealing_given,its_accuracy
concept,is_very_appealing_given,its_high_accuracy_coupled
it,is_implemented_at,increased_risk_of_breast_cancer
it,is_only_routinely_implemented_at,increased_risk
Efforts,develop,MRI_protocols
it,is,only_routinely_implemented_in_screening_of_women_at_risk_of_breast_cancer
concept,Therefore_is_very_appealing_given,its_high_diagnostic_accuracy
concept,Therefore_is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
concept,Therefore_is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction
cornerstone,defines_value_as,patient_'s_outcome
concept,is_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
long_time,However_limit,its_widespread_use
it,is,Hence_routinely_implemented_in_screening_of_women_at_risk
studies,are,necessary_results
MRI,is,most_sensitive_test
it,Hence_is_currently_implemented_at,risk_of_breast_cancer
concept,Therefore_is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction
it,is,Hence_currently_only_routinely_implemented
it,seems,feasible
it,Hence_is_currently_implemented_at,increased_risk
concept,is,Therefore_appealing
concept,is_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
it,is,currently_implemented_in_screening_of_women_at_increased_risk
article,give,overview
concept,is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
it,is_currently_routinely_implemented_at,risk_of_breast_cancer
concept,Therefore_is_very_appealing_given,its_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
it,is,currently_routinely_implemented
concept,is_very_appealing_given,its_high_accuracy_coupled_with_possibility
larger_studies,are_results_with,MRI_protocols
it,is,Hence_currently_routinely_implemented_in_screening_at_increased_risk
it,is,Hence_only_routinely_implemented_in_screening_of_women_at_risk_of_breast_cancer
it,is,currently_only_routinely_implemented_in_screening_at_risk_of_breast_cancer
it,is,Hence_currently_routinely_implemented_in_screening_of_women_at_risk
it,is,currently_only_routinely_implemented_in_screening_at_increased_risk
it,is_only_routinely_implemented_at,increased_risk_of_breast_cancer
it,is,routinely_implemented
it,is,Hence_currently_implemented_in_screening_of_women_at_increased_risk
concept,Therefore_is_appealing_given,its_diagnostic_accuracy
concept,Therefore_is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
limitations,abbreviated,DCE
concept,Therefore_is_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
concerns,are,are_investigated
scan_time,limit,its_use
concept,is_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction_in_cost
breast,MRI_of_is,sensitive_test_for_breast_cancer_detection
concept,Therefore_is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction
concept,is_very_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction
it,is,currently_routinely_implemented_in_screening_at_increased_risk
concept,Therefore_is_appealing_given,its_accuracy_coupled_with_possibility
it,is,currently_implemented
larger_studies,are_initial_results_with,MRI_protocols
it,is,Hence_routinely_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
it,is,implemented_in_screening_of_women_at_risk_of_breast_cancer
concept,Therefore_is_very_appealing_given,its_diagnostic_accuracy
it,is,routinely_implemented_in_screening_of_women_at_increased_risk
concept,Therefore_is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction
it,Hence_is_implemented_at,increased_risk
concept,Therefore_is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
it,is,Hence_implemented_in_screening_at_risk_of_breast_cancer
it,is,currently_only_routinely_implemented_in_screening_of_women_at_risk_of_breast_cancer
larger_prospective_studies,are_necessary_initial_results_with,MRI_protocols
cornerstone,defines,value
studies,are_necessary_results_with,abbreviated_MRI_protocols
it,is,Hence_currently_only_routinely_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
larger_studies,are,initial_results
high_costs,However_limit,its_use
it,is,Hence_routinely_implemented_in_screening_at_increased_risk
concept,Therefore_is_very_appealing_given,its_high_accuracy_coupled_with_possibility
it,is,only_routinely_implemented_in_screening_at_increased_risk
MRI,outperforms_imaging_with,mammography_breast_tomosynthesis
it,is,Hence_routinely_implemented_in_screening_of_women_at_increased_risk
breast,MRI_of_is,sensitive_test
concept,Therefore_is_appealing_given,its_high_accuracy_coupled
breast,MRI_of_is,test_for_breast_cancer_detection
it,is,Hence_implemented_in_screening_of_women_at_risk_of_breast_cancer
recent_concerns,are,are_investigated
it,is,currently_only_routinely_implemented_in_screening_at_risk
concept,is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
concept,Therefore_is_very_appealing_given,its_high_accuracy_coupled
MRI,is_most_sensitive_test_for,breast_cancer_detection
cornerstone,defines_value_as,patient_'s_outcome_over_costs
concept,Therefore_is_appealing_given,its_accuracy_coupled_with_possibility_of_reduction
it,is,implemented_in_screening_at_increased_risk
scan_time,limit,its_widespread_use
it,is,Hence_implemented_in_screening_at_risk
concept,is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
concept,is_very_appealing_given,its_high_diagnostic_accuracy_coupled
concept,is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility
concept,is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
it,is,implemented_in_screening_of_women_at_risk
it,is,Hence_only_routinely_implemented_in_screening_at_risk_of_breast_cancer
it,is,Hence_currently_implemented
it,is_currently_implemented_at,risk
concept,is_very_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
concept,is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
it,Hence_is_currently_implemented_at,increased_risk_of_breast_cancer
concept,is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility
it,Hence_is_only_routinely_implemented_in,screening
concept,Therefore_is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
time,limit,its_widespread_use
breast,MRI_of_is,test
it,is,currently_routinely_implemented_in_screening_of_women_at_risk
concept,Therefore_is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
concept,Therefore_is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction
concept,is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction
concept,is_appealing_given,its_high_accuracy_coupled_with_possibility
it,is,Hence_only_routinely_implemented_in_screening_at_increased_risk
it,is,Hence_currently_only_routinely_implemented_in_screening_of_women_at_increased_risk
concept,is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction
high_costs,limit,its_use
concept,Therefore_is_very_appealing_given,its_accuracy_coupled
it,is_currently_routinely_implemented_at,increased_risk_of_breast_cancer
it,Hence_is_currently_routinely_implemented_in,screening
concept,is,appealing
important_cornerstone,defines_value_as,patient_'s_outcome_over_costs
it,is,routinely_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
it,is,Hence_implemented_in_screening_at_increased_risk_of_breast_cancer
appropriateness,quality_of,imaging
breast,MRI_of_is,most_sensitive_test_for_breast_cancer_detection
it,is_currently_implemented_in,screening_of_women
it,is_currently_only_routinely_implemented_at,risk_of_breast_cancer
it,is_only_routinely_implemented_at,risk
it,is,Hence_currently_implemented_in_screening_at_risk
concept,is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility
concept,Therefore_is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost
concept,is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction
it,Hence_is_currently_only_routinely_implemented_at,risk_of_breast_cancer
MRI,is_sensitive_test_for,breast_cancer_detection
it,is,Hence_currently_routinely_implemented_in_screening_at_risk
it,is_currently_implemented_at,increased_risk_of_breast_cancer
it,is_currently_routinely_implemented_in,screening
it,is,Hence_currently_routinely_implemented_in_screening_of_women_at_risk_of_breast_cancer
it,is_implemented_at,risk
concerns,are,are_also_investigated
concept,Therefore_is_very_appealing_given,its_accuracy_coupled_with_possibility_of_reduction
concept,is_appealing_given,its_accuracy_coupled
it,is,Hence_routinely_implemented
it,is,currently_implemented_in_screening_of_women_at_risk_of_breast_cancer
larger_studies,are_necessary_results_with,MRI_protocols
concept,Therefore_is_very_appealing_given,its_accuracy_coupled_with_possibility_of_reduction_in_cost
it,is,Hence_implemented_in_screening_of_women_at_risk
concept,is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
it,is_implemented_in,screening
it,Hence_is_currently_only_routinely_implemented_at,risk
it,Hence_is_implemented_at,increased_risk_of_breast_cancer
it,is,currently_only_routinely_implemented_in_screening_at_increased_risk_of_breast_cancer
concept,is_appealing_given,its_diagnostic_accuracy
concept,Therefore_is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction_in_cost
it,is_currently_routinely_implemented_at,increased_risk
it,is,currently_only_routinely_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
it,is_currently_only_routinely_implemented_at,risk
concept,Therefore_is_very_appealing_given,its_accuracy_coupled_with_possibility
it,is_currently_only_routinely_implemented_in,screening_of_women
it,is_implemented_in,screening_of_women
it,is,Hence_only_routinely_implemented_in_screening_at_risk
important_cornerstone,defines,value
prospective_studies,are_results_with,abbreviated_MRI_protocols
it,is,routinely_implemented_in_screening_at_risk_of_breast_cancer
prospective_studies,are_results_with,MRI_protocols
concept,Therefore_is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost
concept,Therefore_is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction
it,is,implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
it,is_only_routinely_implemented_in,screening
costs,However_limit,its_widespread_use
concept,Therefore_is_appealing_given,its_high_accuracy
it,Hence_is_implemented_in,screening_of_women
it,is,currently_routinely_implemented_in_screening_at_risk
it,is,Hence_currently_routinely_implemented_in_screening_at_increased_risk_of_breast_cancer
it,is,Hence_currently_routinely_implemented_in_screening_at_risk_of_breast_cancer
it,is,Hence_only_routinely_implemented_in_screening_at_increased_risk_of_breast_cancer
larger_studies,are_necessary_initial_results_with,MRI_protocols
concept,is_very_appealing_given,its_accuracy_coupled_with_possibility_of_reduction
scan_time,However_limit,its_widespread_use
concept,is_appealing_given,its_diagnostic_accuracy_coupled
it,is,Hence_currently_only_routinely_implemented_in_screening_of_women_at_risk
prospective_studies,are,initial_results
concept,is_appealing_given,its_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
MRI,is,test
it,is,Hence_routinely_implemented_in_screening_at_risk
concept,Therefore_is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility
concept,Therefore_is_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction_in_cost
concept,Therefore_is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
it,is,Hence_currently_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
it,Hence_is_currently_routinely_implemented_at,increased_risk
concept,Therefore_is_very_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction
it,is,currently_routinely_implemented_in_screening_of_women_at_increased_risk
larger_prospective_studies,are,results
it,Hence_is_currently_only_routinely_implemented_at,increased_risk_of_breast_cancer
concept,Therefore_is_appealing_given,its_diagnostic_accuracy_coupled
it,is,routinely_implemented_in_screening_of_women_at_risk
it,is,currently_only_routinely_implemented_in_screening_of_women_at_risk
it,Hence_is_currently_routinely_implemented_at,risk_of_breast_cancer
concept,is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility
necessary_initial_results,is_with,abbreviated_MRI_protocols
it,is_only_routinely_implemented_at,risk_of_breast_cancer
it,Hence_is_currently_only_routinely_implemented_at,increased_risk
concept,is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction
important_cornerstone,defines_value_as,patient_'s_outcome
concept,is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost
it,is_currently_routinely_implemented_in,screening_of_women
concept,Therefore_is_very_appealing_given,its_accuracy
it,is,only_routinely_implemented_in_screening_of_women_at_risk
recent_concerns,are,are_also_investigated_for_breast_cancer_diagnosis
it,is,Hence_implemented_in_screening_at_increased_risk
concept,is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
Efforts,develop,abbreviated_MRI_protocols
concept,Therefore_is_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
costs,limit,its_use
it,is,Hence_currently_routinely_implemented
concept,Therefore_is_appealing_given,its_accuracy_coupled_with_possibility_of_reduction_in_cost
it,is,currently_implemented_in_screening_at_increased_risk
concept,Therefore_is_appealing_given,its_accuracy_coupled
it,Hence_is_only_routinely_implemented_at,increased_risk
concept,is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
concept,is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost
concept,is_very_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
studies,are,results
it,is_currently_only_routinely_implemented_at,increased_risk_of_breast_cancer
it,is,routinely_implemented_in_screening_of_women_at_risk_of_breast_cancer
it,Hence_is_currently_only_routinely_implemented_in,screening
studies,are_initial_results_with,MRI_protocols
it,Hence_is_routinely_implemented_in,screening_of_women
concept,Therefore_is_appealing_given,its_high_diagnostic_accuracy_coupled
it,Hence_is_currently_only_routinely_implemented_in,screening_of_women
studies,are_results_with,abbreviated_MRI_protocols
studies,are_necessary_initial_results_with,MRI_protocols
it,is,Hence_only_routinely_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
long_scan_time,limit,its_use
high_costs,limit,its_widespread_use
concept,is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction
time,However_limit,its_use
it,is,Hence_currently_routinely_implemented_in_screening_of_women_at_increased_risk
concept,Therefore_is_appealing_given,its_high_accuracy_coupled_with_possibility
concept,Therefore_is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_reduction
studies,are_necessary_results_with,MRI_protocols
it,Hence_is_only_routinely_implemented_at,risk
concept,is_appealing_given,its_accuracy_coupled_with_possibility_of_reduction_in_cost
concept,is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
concept,Therefore_is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
prospective_studies,are_necessary_results_with,MRI_protocols
it,is,routinely_implemented_in_screening_at_increased_risk
prospective_studies,are,necessary_results
it,is,currently_implemented_in_screening_of_women_at_risk
prospective_studies,are,results
it,is_implemented_at,risk_of_breast_cancer
it,is,implemented
concept,Therefore_is_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
concept,is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
concept,is_very_appealing_given,its_diagnostic_accuracy_coupled
time,However_limit,its_widespread_use
it,Hence_is_routinely_implemented_at,increased_risk_of_breast_cancer
larger_prospective_studies,are,initial_results
it,is,currently_only_routinely_implemented_in_screening_of_women_at_increased_risk
marked_reduction,is_in,cost_of_MRI_examination
MRI,outperforms,imaging
it,is,currently_routinely_implemented_in_screening_of_women_at_risk_of_breast_cancer
it,is,currently_implemented_in_screening_at_risk_of_breast_cancer
it,is,Hence_currently_only_routinely_implemented_in_screening_at_risk
concept,Therefore_is_appealing_given,its_accuracy
it,Hence_is_routinely_implemented_at,risk_of_breast_cancer
it,is_currently_implemented_in,screening
concept,is_appealing_given,its_high_accuracy_coupled
concept,is_very_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
concept,is_very_appealing_given,its_diagnostic_accuracy
concerns,are,are_investigated_for_breast_cancer_diagnosis
it,is,Hence_currently_implemented_in_screening_at_increased_risk_of_breast_cancer
it,Hence_is_routinely_implemented_at,risk
it,is,only_routinely_implemented_in_screening_at_increased_risk_of_breast_cancer
limitations,abbreviated,contrast-enhanced
it,is,routinely_implemented_in_screening_at_increased_risk_of_breast_cancer
concept,Therefore_is_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction
concept,is_appealing_given,its_high_accuracy_coupled_with_possibility_of_reduction
it,is_implemented_at,increased_risk
it,is,implemented_in_screening_of_women_at_increased_risk
it,is,currently_only_routinely_implemented
concept,is,very_appealing
it,is,Hence_currently_routinely_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
concept,Therefore_is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
it,Hence_is_currently_routinely_implemented_at,increased_risk_of_breast_cancer
it,Hence_is_implemented_in,screening
article,give,overview_of_breast_MRI_protocols
it,is,Hence_currently_implemented_in_screening_at_increased_risk
it,is,Hence_currently_implemented_in_screening_of_women_at_risk_of_breast_cancer
concept,is_very_appealing_given,its_accuracy_coupled_with_possibility
concept,Therefore_is_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction
concerns,are,are_also_investigated_for_breast_cancer_diagnosis
prospective_studies,are_initial_results_with,MRI_protocols
it,is,implemented_in_screening_at_increased_risk_of_breast_cancer
it,Hence_is_currently_implemented_at,risk
concept,Therefore_is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
concept,is_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction
it,is,Hence_routinely_implemented_in_screening_of_women_at_risk_of_breast_cancer
larger_prospective_studies,are_necessary_results_with,abbreviated_MRI_protocols
concept,is_appealing_given,its_accuracy_coupled_with_possibility_of_reduction
concept,is_very_appealing_given,its_accuracy_coupled
concept,is_very_appealing_given,its_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
concept,is_appealing_given,its_high_accuracy_coupled_with_possibility_of_marked_reduction
long_scan_time,limit,its_widespread_use
it,is,Hence_only_routinely_implemented_in_screening_of_women_at_risk
concept,is_very_appealing_given,its_high_diagnostic_accuracy
costs,limit,its_widespread_use
larger_prospective_studies,are_results_with,MRI_protocols
studies,are_results_with,MRI_protocols
concept,Therefore_is_very_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
it,is,Hence_currently_implemented_in_screening_of_women_at_risk
concept,Therefore_is_very_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
it,is_routinely_implemented_in,screening
concept,is_very_appealing_given,its_accuracy_coupled_with_possibility_of_marked_reduction_in_cost
larger_studies,are,necessary_initial_results
concept,is_very_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction
larger_studies,are_necessary_results_with,abbreviated_MRI_protocols
concept,Therefore_is_appealing_given,its_high_diagnostic_accuracy
it,is,routinely_implemented_in_screening_at_risk
it,Hence_is_implemented_at,risk
concept,Therefore_is_very_appealing_given,its_diagnostic_accuracy_coupled
it,is_routinely_implemented_at,risk_of_breast_cancer
it,is,currently_implemented_in_screening_at_increased_risk_of_breast_cancer
recent_concerns,are,are_also_investigated
prospective_studies,are_necessary_initial_results_with,MRI_protocols
it,is,currently_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
long_time,limit,its_widespread_use
it,is,only_routinely_implemented_in_screening_of_women_at_increased_risk_of_breast_cancer
it,Hence_is_only_routinely_implemented_at,risk_of_breast_cancer
it,is,Hence_routinely_implemented_in_screening_at_increased_risk_of_breast_cancer
concept,Therefore_is_appealing_given,its_high_diagnostic_accuracy_coupled_with_possibility_of_marked_reduction_in_cost_of_MRI_examination
concept,Therefore_is_appealing_given,its_diagnostic_accuracy_coupled_with_possibility_of_reduction_in_cost_of_MRI_examination
it,Hence_is_currently_routinely_implemented_in,screening_of_women
it,Hence_is_routinely_implemented_in,screening
it,Hence_is_only_routinely_implemented_in,screening_of_women
They,did_find,risk_with_use_of_levonorgestrel_intrauterine_system-both_of_potentially_important_findings
Danish_cohort_study,reported,risk_among_current_contraception_users
They,did_find,risk_with_use
breast_cancer_effects,described_now_in,multiple_studies
recent_Danish_cohort_study,reported,increased_risk_of_breast_cancer_among_hormonal_contraception_users
They,did_find,risk
recent_cohort_study,reported,risk
They,did_find,risk_with_use_of_levonorgestrel_intrauterine_system-both_of_important_findings
recent_cohort_study,reported,increased_risk_of_breast_cancer_among_contraception_users
recent_cohort_study,reported,risk_among_current_contraception_users
Danish_cohort_study,reported,increased_risk_of_breast_cancer
recent_cohort_study,reported,20_%_risk_among_hormonal_contraception_users
recent_Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer
recent_Danish_cohort_study,reported,20_%_increased_risk_among_contraception_users
cohort_study,reported,increased_risk_of_breast_cancer_among_contraception_users
They,did_find,increased_risk
They,did_find,increased_risk_with_use_of_levonorgestrel_system-both_of_important_findings
cohort_study,reported,risk_of_breast_cancer_among_current_contraception_users
Danish_cohort_study,reported,risk_of_breast_cancer_among_current_hormonal_contraception_users
cohort_study,reported,risk_of_breast_cancer_among_current_hormonal_contraception_users
cohort_study,reported,increased_risk
recent_Danish_cohort_study,reported,risk_of_breast_cancer_among_hormonal_contraception_users
cohort_study,reported,increased_risk_among_current_contraception_users
recent_cohort_study,reported,20_%_risk_of_breast_cancer_among_hormonal_contraception_users
breast_cancer_effects,described_in,multiple_studies
recent_cohort_study,reported,increased_risk_among_hormonal_contraception_users
Danish_cohort_study,reported,20_%_increased_risk_among_contraception_users
recent_Danish_cohort_study,reported,risk
Danish_cohort_study,reported,increased_risk_of_breast_cancer_among_contraception_users
cohort_study,reported,increased_risk_of_breast_cancer_among_hormonal_contraception_users
They,did_find,risk_with_use_of_levonorgestrel_system-both_of_important_findings
They,did_find,increased_risk_with_use_of_levonorgestrel_system-both_of_potentially_important_findings
cohort_study,reported,increased_risk_among_contraception_users
Danish_cohort_study,reported,20_%_risk
Danish_cohort_study,reported,20_%_risk_among_contraception_users
Danish_cohort_study,reported,risk
recent_cohort_study,reported,risk_of_breast_cancer_among_current_contraception_users
recent_Danish_cohort_study,reported,increased_risk_of_breast_cancer_among_current_contraception_users
They,did_find,risk_with_use_of_levonorgestrel_system-both
results,are_consistent_with,studies
Danish_cohort_study,reported,risk_of_breast_cancer_among_current_contraception_users
Danish_cohort_study,reported,increased_risk_among_current_hormonal_contraception_users
cohort_study,reported,20_%_increased_risk_of_breast_cancer
cohort_study,reported,20_%_risk_of_breast_cancer_among_hormonal_contraception_users
They,did_find,increased_risk_with_use_of_levonorgestrel_system-both_of_findings
recent_cohort_study,reported,20_%_risk_among_current_hormonal_contraception_users
recent_cohort_study,reported,20_%_risk_among_contraception_users
cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_current_contraception_users
They,did_find,risk_with_use_of_levonorgestrel_system-both_of_findings
Danish_cohort_study,reported,20_%_risk_of_breast_cancer_among_hormonal_contraception_users
recent_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_current_contraception_users
Danish_cohort_study,reported,increased_risk
recent_cohort_study,reported,increased_risk_of_breast_cancer_among_hormonal_contraception_users
Danish_cohort_study,reported,20_%_risk_of_breast_cancer_among_current_contraception_users
recent_Danish_cohort_study,reported,risk_among_contraception_users
risk,is_in,current_users_of_longer_duration
breast_cancer_effects,described_now_in,studies
recent_cohort_study,reported,20_%_increased_risk_among_hormonal_contraception_users
recent_cohort_study,reported,increased_risk_of_breast_cancer_among_current_contraception_users
Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_current_hormonal_contraception_users
recent_Danish_cohort_study,reported,20_%_risk_of_breast_cancer_among_current_hormonal_contraception_users
recent_cohort_study,reported,risk_of_breast_cancer_among_current_hormonal_contraception_users
They,did_find,risk_with_use_of_levonorgestrel_system-both_of_potentially_important_findings
cohort_study,reported,risk_among_contraception_users
recent_cohort_study,reported,20_%_risk_of_breast_cancer_among_contraception_users
recent_cohort_study,reported,risk_of_breast_cancer
recent_cohort_study,reported,20_%_increased_risk_among_current_contraception_users
cohort_study,reported,risk_of_breast_cancer_among_hormonal_contraception_users
cohort_study,reported,risk_among_hormonal_contraception_users
recent_cohort_study,reported,increased_risk_among_current_contraception_users
Danish_cohort_study,reported,increased_risk_of_breast_cancer_among_current_hormonal_contraception_users
Danish_cohort_study,reported,increased_risk_among_hormonal_contraception_users
cohort_study,reported,risk_of_breast_cancer
recent_cohort_study,reported,20_%_increased_risk_of_breast_cancer
recent_Danish_cohort_study,reported,risk_of_breast_cancer
cohort_study,reported,20_%_risk_of_breast_cancer_among_current_contraception_users
Danish_cohort_study,reported,20_%_risk_among_current_hormonal_contraception_users
recent_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_current_hormonal_contraception_users
recent_Danish_cohort_study,reported,20_%_risk_of_breast_cancer
cohort_study,reported,increased_risk_of_breast_cancer_among_current_hormonal_contraception_users
cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_contraception_users
cohort_study,reported,risk_of_breast_cancer_among_contraception_users
recent_Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_current_contraception_users
cohort_study,reported,20_%_risk_among_current_hormonal_contraception_users
recent_Danish_cohort_study,reported,risk_among_hormonal_contraception_users
recent_cohort_study,reported,20_%_risk_of_breast_cancer
recent_cohort_study,reported,20_%_increased_risk_among_contraception_users
recent_Danish_cohort_study,reported,20_%_increased_risk
recent_Danish_cohort_study,reported,20_%_risk
recent_cohort_study,reported,increased_risk
Danish_cohort_study,reported,increased_risk_of_breast_cancer_among_current_contraception_users
cohort_study,reported,increased_risk_of_breast_cancer
cohort_study,reported,20_%_increased_risk_among_current_contraception_users
recent_cohort_study,reported,20_%_risk_of_breast_cancer_among_current_hormonal_contraception_users
Danish_cohort_study,reported,20_%_risk_of_breast_cancer
cohort_study,reported,risk_among_current_contraception_users
cohort_study,reported,20_%_risk_among_contraception_users
cohort_study,reported,20_%_risk_among_current_contraception_users
recent_Danish_cohort_study,reported,20_%_risk_of_breast_cancer_among_contraception_users
Danish_cohort_study,reported,20_%_risk_of_breast_cancer_among_current_hormonal_contraception_users
recent_Danish_cohort_study,reported,risk_of_breast_cancer_among_contraception_users
cohort_study,reported,20_%_risk_of_breast_cancer_among_current_hormonal_contraception_users
results,are_consistent_with,previous_studies
results,are_largely_consistent_with,previous_studies
cohort_study,reported,20_%_increased_risk_among_contraception_users
recent_Danish_cohort_study,reported,increased_risk_among_current_contraception_users
cohort_study,reported,20_%_increased_risk_among_hormonal_contraception_users
recent_Danish_cohort_study,reported,increased_risk_among_current_hormonal_contraception_users
cohort_study,reported,risk
Danish_cohort_study,reported,20_%_increased_risk_among_hormonal_contraception_users
recent_Danish_cohort_study,reported,20_%_increased_risk_among_hormonal_contraception_users
They,did_find,increased_risk_with_use_of_levonorgestrel_system-both
recent_Danish_cohort_study,reported,20_%_risk_among_contraception_users
recent_Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_contraception_users
recent_Danish_cohort_study,reported,risk_of_breast_cancer_among_current_contraception_users
recent_Danish_cohort_study,reported,20_%_risk_of_breast_cancer_among_hormonal_contraception_users
Danish_cohort_study,reported,20_%_increased_risk_among_current_contraception_users
breast_cancer_effects_wane,has,has_found
Danish_cohort_study,reported,20_%_risk_of_breast_cancer_among_contraception_users
cohort_study,reported,increased_risk_of_breast_cancer_among_current_contraception_users
Danish_cohort_study,reported,risk_among_current_hormonal_contraception_users
recent_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_contraception_users
recent_cohort_study,reported,risk_among_current_hormonal_contraception_users
cohort_study,reported,20_%_increased_risk
Danish_cohort_study,reported,20_%_increased_risk
recent_Danish_cohort_study,reported,20_%_risk_of_breast_cancer_among_current_contraception_users
recent_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_hormonal_contraception_users
Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer
They,did_find,increased_risk_with_use_of_levonorgestrel_intrauterine_system-both_of_findings
results,are,largely_consistent
recent_Danish_cohort_study,reported,20_%_risk_among_hormonal_contraception_users
Danish_cohort_study,reported,risk_of_breast_cancer_among_contraception_users
recent_Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_current_hormonal_contraception_users
Danish_cohort_study,reported,20_%_risk_among_hormonal_contraception_users
Danish_cohort_study,reported,risk_among_hormonal_contraception_users
They,did_find,increased_risk_with_use_of_levonorgestrel_intrauterine_system-both_of_potentially_important_findings
recent_cohort_study,reported,20_%_risk_of_breast_cancer_among_current_contraception_users
recent_Danish_cohort_study,reported,increased_risk_among_contraception_users
recent_cohort_study,reported,20_%_risk
recent_cohort_study,reported,risk_of_breast_cancer_among_contraception_users
cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_current_hormonal_contraception_users
recent_cohort_study,reported,risk_among_contraception_users
recent_Danish_cohort_study,reported,20_%_increased_risk_among_current_hormonal_contraception_users
recent_cohort_study,reported,risk_among_hormonal_contraception_users
recent_cohort_study,reported,increased_risk_among_contraception_users
Danish_cohort_study,reported,increased_risk_of_breast_cancer_among_hormonal_contraception_users
cohort_study,reported,risk_among_current_hormonal_contraception_users
Danish_cohort_study,reported,20_%_increased_risk_among_current_hormonal_contraception_users
Danish_cohort_study,reported,risk_of_breast_cancer
results,are_largely_consistent_with,studies
Danish_cohort_study,reported,20_%_risk_among_current_contraception_users
recent_Danish_cohort_study,reported,20_%_risk_among_current_hormonal_contraception_users
recent_Danish_cohort_study,reported,20_%_increased_risk_among_current_contraception_users
breast_cancer_effects,described_in,studies
cohort_study,reported,increased_risk_among_hormonal_contraception_users
Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_hormonal_contraception_users
Danish_cohort_study,reported,increased_risk_among_current_contraception_users
recent_Danish_cohort_study,reported,risk_of_breast_cancer_among_current_hormonal_contraception_users
recent_Danish_cohort_study,reported,risk_among_current_hormonal_contraception_users
They,did_find,increased_risk_with_use_of_levonorgestrel_intrauterine_system-both
cohort_study,reported,20_%_risk_among_hormonal_contraception_users
results,are,consistent
cohort_study,reported,increased_risk_among_current_hormonal_contraception_users
recent_cohort_study,reported,20_%_increased_risk
recent_cohort_study,reported,increased_risk_of_breast_cancer
They,did_find,increased_risk_with_use
Danish_cohort_study,reported,risk_of_breast_cancer_among_hormonal_contraception_users
cohort_study,reported,20_%_risk_of_breast_cancer
cohort_study,reported,20_%_increased_risk_among_current_hormonal_contraception_users
Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_current_contraception_users
They,did_find,risk_with_use_of_levonorgestrel_intrauterine_system-both
recent_cohort_study,reported,increased_risk_of_breast_cancer_among_current_hormonal_contraception_users
cohort_study,reported,20_%_risk_of_breast_cancer_among_contraception_users
recent_Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_hormonal_contraception_users
recent_cohort_study,reported,increased_risk_among_current_hormonal_contraception_users
recent_Danish_cohort_study,reported,increased_risk_among_hormonal_contraception_users
recent_Danish_cohort_study,reported,increased_risk_of_breast_cancer_among_current_hormonal_contraception_users
They,did_find,increased_risk_with_use_of_levonorgestrel_intrauterine_system-both_of_important_findings
recent_Danish_cohort_study,reported,increased_risk_of_breast_cancer_among_contraception_users
increased_risk,is_with,use_of_levonorgestrel_intrauterine_system-both_of_potentially_important_findings
recent_cohort_study,reported,20_%_increased_risk_among_current_hormonal_contraception_users
recent_Danish_cohort_study,reported,increased_risk_of_breast_cancer
They,did_find,risk_with_use_of_levonorgestrel_intrauterine_system-both_of_findings
cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_hormonal_contraception_users
Danish_cohort_study,reported,20_%_increased_risk_of_breast_cancer_among_contraception_users
recent_cohort_study,reported,20_%_risk_among_current_contraception_users
recent_Danish_cohort_study,reported,20_%_risk_among_current_contraception_users
recent_Danish_cohort_study,reported,increased_risk
recent_cohort_study,reported,risk_of_breast_cancer_among_hormonal_contraception_users
recent_Danish_cohort_study,reported,risk_among_current_contraception_users
Danish_cohort_study,reported,increased_risk_among_contraception_users
cohort_study,reported,20_%_risk
Danish_cohort_study,reported,risk_among_contraception_users
X-ray_mammography,has,sensitivity_for_women
tomography_magnetic_resonance_imaging,being,used
X-ray_mammography,has,diagnostic_sensitivity_for_women_with_dense_breasts
AION,were,formed_by_co-encapsulation_in_micelles
study,indicates,potential_of_AION_as_effective_multimodal_contrast_agent_for_breast_cancer_diagnosis
Conventional_X-ray_mammography,has,low_diagnostic_sensitivity_for_women
study,indicates,potential
Conventional_X-ray_mammography,has,diagnostic_sensitivity_for_women_with_breasts
AION,were,formed_by_co-encapsulation_of_fluorophore_in_micelles
agreement,is_with,its_minimal_silver_ion_release_profiles
AION,allowed,tumor_imaging
study,indicates,potential_as_effective_multimodal_contrast_agent_for_breast_cancer_diagnosis
study,indicates,potential_as_contrast_agent_for_breast_cancer_diagnosis
women,is_with,dense_breasts
X-ray_mammography,has,low_diagnostic_sensitivity_for_women_with_breasts
AION,allowed_tumor_imaging,evidenced_by_increase_in_contrast
study,indicates,potential_of_AION_as_effective_multimodal_contrast_agent
strong_contrast,is_with,imaging_modalities
AION,were,formed_by_co-encapsulation_of_near-infrared_fluorophore_in_PEGylated_micelles
address,issues_of,existing_contrast_agents
AION,allowed,evidenced
AION,allowed_tumor_imaging,evidenced_by_increase
study,indicates,potential_as_multimodal_contrast_agent_for_breast_cancer_diagnosis
study,indicates,potential_of_AION
Conventional_X-ray_mammography,has,low_sensitivity
study,indicates,potential_as_multimodal_contrast_agent
X-ray_mammography,has,low_sensitivity_for_women
AION,allowed,evidenced_by_increase_in_contrast
AION,allowed,evidenced_by_increase_in_contrast_after_injection
AION,allowed_tumor_imaging,evidenced
imaging_technique,requires,different_contrast_agent
AION,generated,contrast_with_imaging_modalities
X-ray_mammography,has,sensitivity_for_women_with_dense_breasts
study,indicates,potential_as_effective_contrast_agent
AION,allowed,evidenced_by_increase
available_contrast_agents,are,non-ideal
X-ray_mammography,has,low_diagnostic_sensitivity_for_women_with_dense_breasts
X-ray_mammography,has,low_sensitivity
X-ray_mammography,has,low_diagnostic_sensitivity
Conventional_X-ray_mammography,has,low_sensitivity_for_women_with_dense_breasts
Conventional_X-ray_mammography,has,sensitivity_for_women_with_dense_breasts
study,indicates,potential_of_AION_as_multimodal_contrast_agent_for_breast_cancer_diagnosis
AION,allowed_tumor_imaging,evidenced_by_increase_in_contrast_after_injection
X-ray_mammography,has,low_sensitivity_for_women_with_dense_breasts
AION,demonstrated_in,imaging
X-ray_mammography,has,sensitivity_for_women_with_breasts
Conventional_X-ray_mammography,has,low_diagnostic_sensitivity_for_women_with_dense_breasts
study,indicates,potential_of_AION_as_contrast_agent
X-ray_mammography,has,sensitivity
screening_tools,computed_As,result
AION,allowed,in_tumor_imaging
X-ray_mammography,has,diagnostic_sensitivity
AION,demonstrated_in,phantom_imaging
X-ray_mammography,has,low_sensitivity_for_women_with_breasts
study,indicates,potential_of_AION_as_effective_contrast_agent_for_breast_cancer_diagnosis
Conventional_X-ray_mammography,has,sensitivity_for_women
study,indicates,potential_of_AION_as_effective_contrast_agent
study,indicates,potential_as_contrast_agent
Conventional_X-ray_mammography,has,sensitivity_for_women_with_breasts
breast_imaging_modality,address,issues
increase,is_in,contrast_after_injection
AION,were,formed_by_co-encapsulation_in_PEGylated_micelles
AION,were,formed
tomography_resonance_imaging,being,used
Conventional_X-ray_mammography,has,diagnostic_sensitivity_for_women_with_dense_breasts
X-ray_mammography,has,diagnostic_sensitivity_for_women
study,indicates,potential_of_AION_as_contrast_agent_for_breast_cancer_diagnosis
X-ray_mammography,has,low_diagnostic_sensitivity_for_women
study,indicates,potential_as_effective_contrast_agent_for_breast_cancer_diagnosis
breast_imaging_modality,address,issues_of_contrast_agents
AION,evidenced_by,increase_in_contrast_after_injection
Conventional_X-ray_mammography,has,diagnostic_sensitivity_for_women
Conventional_X-ray_mammography,has,low_diagnostic_sensitivity
AION,generated,strong_contrast_with_imaging_modalities
AION,evidenced_by,increase_in_contrast
Conventional_X-ray_mammography,has,diagnostic_sensitivity
address,issues_of,contrast_agents
AION,were_formed_by,co-encapsulation_of_fluorophore
AION,were_formed_in,PEGylated_micelles
Conventional_X-ray_mammography,has,low_sensitivity_for_women_with_breasts
contrast_agents,are,non-ideal
breast_imaging_modality,address,issues_of_existing_contrast_agents
AION,were_formed_by,co-encapsulation_of_near-infrared_fluorophore
breast_imaging_modality,simplify,diagnosis_process
Conventional_X-ray_mammography,has,sensitivity
tomography_magnetic_resonance_imaging,being,used_for_women
AION,were_formed_by,co-encapsulation
study,indicates,potential_of_AION_as_multimodal_contrast_agent
tomography_resonance_imaging,being,used_for_women
AION,were,formed_by_co-encapsulation_of_fluorophore_in_PEGylated_micelles
AION,were_formed_in,micelles
AION,evidenced_by,increase
Conventional_X-ray_mammography,has,low_sensitivity_for_women
study,indicates,potential_as_effective_multimodal_contrast_agent
AION,were,formed_by_co-encapsulation_of_near-infrared_fluorophore_in_micelles
X-ray_mammography,has,diagnostic_sensitivity_for_women_with_breasts
imaging_technique,requires,contrast_agent
Conventional_X-ray_mammography,has,low_diagnostic_sensitivity_for_women_with_breasts
studies,were,included
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_dietary_intake_among_women
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women
Our_findings,suggest,evidence_for_significantly_inverse_association
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene
association,has,has_inconsistent
I2,=,38.7_%
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_intake_of_b-carotene_among_women
Our_findings,suggest,evidence_for_inverse_association
improved_breast_cancer_OS,is_with,summary_hazard_ratio_of_0.70_for_highest_intake
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake
adjustment,was,factor
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_intake_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_association_between_prediagnosis_dietary_intake
Our_findings,suggest,limited_evidence_for_inverse_association
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_intake_among_women_with_breast_cancer
Ten_studies,were,included
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_intake
Our_findings,suggest,evidence_for_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women_with_breast_cancer
%_confidence_intervals,were,estimated
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_dietary_intake_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_dietary_intake_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_intake_among_women
intake,assessing,diet
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_association_among_women
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_intake_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_association
Our_findings,suggest,limited_evidence_for_association
adjustment,was_modified_factor_for,association_between_intake_of_b-carotene
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_intake_of_b-carotene
adjustment,was,modified_factor
Ten_studies,were_included_in,meta-analysis
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_intake_among_women
95_%_confidence_intervals,were,estimated
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_association_between_prediagnosis_dietary_intake_among_women_with_breast_cancer
comprehensive_search,was_performed_to,January_31_2018
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_intake_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_inverse_association_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_association_between_prediagnosis_intake_among_women
search,was,performed_from_inception_to_January_31_2018
comprehensive_search,was,performed_from_inception_to_January_31_2018
adjustment,was_factor_for,association_between_intake
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_dietary_intake_of_b-carotene
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene
comprehensive_search,was_performed_from,inception
studies,were_included_in,meta-analysis
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_intake_of_b-carotene
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women
Our_findings,suggest,evidence_for_inverse_association_among_women
Our_findings,suggest,evidence_for_association_between_prediagnosis_dietary_intake_among_women
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_association_among_women
search,was,performed
adjustment,was,modified
Our_findings,suggest,limited_evidence_for_association_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_intake_of_b-carotene_among_women
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_intake_of_b-carotene_among_women
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_intake
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_intake_among_women
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_intake_among_women
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_dietary_intake_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence
search,was_performed_from,inception
Our_findings,suggest,evidence_for_association_between_prediagnosis_dietary_intake_of_b-carotene
Our_findings,suggest,evidence_for_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women
adjustment,was_modified_factor_for,association
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women
summary_hazard_ratios,using,random_effects_model
comprehensive_search,was,performed
adjustment,was_modified_factor_for,association_between_intake
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene
Our_findings,suggest,evidence_for_significantly_inverse_association_among_women_with_breast_cancer
adjustment,was_factor_for,association
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_among_women
Our_findings,suggest,limited_evidence_for_inverse_association_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_association_among_women_with_breast_cancer
women,is_with,breast_cancer
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_dietary_intake
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_intake_of_b-carotene
Our_findings,suggest,limited_evidence_for_significantly_inverse_association
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_intake_of_b-carotene
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_dietary_intake_among_women
Our_findings,suggest,evidence_for_association_between_prediagnosis_intake_of_b-carotene
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_dietary_intake
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_intake
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_association_between_prediagnosis_intake_of_b-carotene_among_women
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_intake
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women
Our_findings,suggest,evidence_for_significantly_inverse_association_among_women
search,was_performed_to,January_31_2018
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_among_women_with_breast_cancer
Our_findings,suggest,evidence
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_intake_of_b-carotene
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_intake_of_b-carotene_among_women
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_among_women
adjustment,was_factor_for,association_between_intake_of_b-carotene
Our_findings,suggest,evidence_for_association_between_prediagnosis_intake
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_dietary_intake_among_women
Our_findings,suggest,limited_evidence_for_significantly_inverse_association_between_prediagnosis_intake_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,limited_evidence_for_association_between_prediagnosis_dietary_intake
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_dietary_intake_among_women
Our_findings,suggest,evidence_for_significantly_inverse_association_between_prediagnosis_intake
Our_findings,suggest,limited_evidence_for_inverse_association_among_women
summary_hazard_ratios,using,effects_model
Our_findings,suggest,limited_evidence_for_inverse_association_between_prediagnosis_intake_among_women
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_intake_of_b-carotene_among_women
Our_findings,suggest,evidence_for_inverse_association_between_prediagnosis_dietary_intake_of_b-carotene_among_women_with_breast_cancer
Our_findings,suggest,evidence_for_association_between_prediagnosis_intake_of_b-carotene_among_women_with_breast_cancer
Ten_studies,is_with,19_450_breast_cancer_cases
Our_findings,suggest,evidence_for_association_between_prediagnosis_intake_among_women_with_breast_cancer
we,assessed,their_ability_in_their_originally_targeted_populations
we,separately_assessed,their_ability_of_prognosis_prediction_in_their_originally_targeted_populations
we,assessed,their_ability_in_their_originally_targeted_populations_of_breast_cancer
Breast_cancer,is_complex_and_heterogeneous_disease_with,variable_molecular_mechanisms_of_carcinogenesis
identification,may_enable,effective_diagnosis
we,assessed,their_ability_of_prognosis_prediction_in_their_populations
signature,is_strong_and_significant_independent_factor_in,cohort
Breast_cancer,is,very_complex_disease
we,separately_assessed,their_ability_in_their_populations_of_breast_cancer
signature,is_independent_factor_in,corresponding_cohort
Breast_cancer,is_disease_with,variable_mechanisms_of_carcinogenesis
Breast_cancer,is_disease_with,variable_molecular_mechanisms
subtype-specific_signature,is_factor_in,corresponding_cohort
Breast_cancer,is_very_complex_disease_with,molecular_mechanisms_of_carcinogenesis
signature,is_strong_independent_factor_in,corresponding_cohort
Breast_cancer,is_complex_and_heterogeneous_disease_with,variable_mechanisms_of_carcinogenesis
we,separately_assessed,their_ability
we,separately_assessed,their_ability_of_prognosis_prediction_in_their_targeted_populations
signature,is_strong_independent_factor_in,cohort
we,summarized,several_signatures
subtype-specific_signature,is_strong_and_significant_independent_prognostic_factor_in,cohort
we,summarized_In,study
signature,is,strong
subtype-specific_signature,is_strong_factor_in,cohort
Breast_cancer,is_very_complex_and_heterogeneous_disease_with,mechanisms_of_carcinogenesis
subtype-specific_signature,is_strong_independent_factor_in,corresponding_cohort
collected_signatures,predict,outcomes_of_positive
signature,is,factor
Breast_cancer,is_very_complex_disease_with,variable_molecular_mechanisms
Breast_cancer,is_complex_and_heterogeneous_disease_with,variable_molecular_mechanisms
we,summarized,gene-expression-based_signatures
subtype-specific_signature,is,strong_prognostic_factor
signature,is,independent
we,summarized_with,value
Breast_cancer,is_disease_with,molecular_mechanisms_of_carcinogenesis
signature,is_strong_and_significant_independent_factor_in,corresponding_cohort
We,identify,subtype-specific_signatures
signature,is_strong_and_significant_independent_prognostic_factor_in,cohort
collected_signatures,predict,outcomes_of_receptor_positive
subtype-specific_signature,is,strong_factor
subtype-specific_signature,is_strong_and_significant_factor_in,cohort
Breast_cancer,is_very_complex_and_heterogeneous_disease_with,variable_mechanisms_of_carcinogenesis
identification,may_enable,diagnosis
subtype-specific_signature,is,independent_prognostic_factor
signature,is_prognostic_factor_in,corresponding_cohort
Breast_cancer,is_very_complex_and_heterogeneous_disease_with,molecular_mechanisms
Breast_cancer,is_complex_disease_with,molecular_mechanisms_of_carcinogenesis
signature,is_strong_and_significant_factor_in,cohort
we,summarized_signatures_with,prognostic_value
we,separately_assessed,their_ability_of_prognosis_prediction_in_their_originally_targeted_populations_of_breast_cancer
signature,is,independent_factor
subtype-specific_signature,is,strong_independent_prognostic_factor
Breast_cancer,is_very_complex_disease_with,molecular_mechanisms
subtype-specific_signature,is_strong_prognostic_factor_in,corresponding_cohort
subtype-specific_signature,is_strong_prognostic_factor_in,cohort
signature,is_strong_prognostic_factor_in,corresponding_cohort
signature,is_strong_and_significant_factor_in,corresponding_cohort
we,summarized_signatures_In,study
we,separately_assessed,their_ability_of_prognosis_prediction
subtype-specific_signature,is_prognostic_factor_in,cohort
we,summarized,several_gene-expression-based_signatures
subtype-specific_signature,is_strong_and_significant_factor_in,corresponding_cohort
signature,is_strong_factor_in,corresponding_cohort
subtype-specific_signature,is_prognostic_factor_in,corresponding_cohort
subtype-specific_signature,is_factor_in,cohort
Breast_cancer,is_very_complex_and_heterogeneous_disease_with,variable_molecular_mechanisms_of_carcinogenesis
collected_signatures,were,originally_designed
signature,is_strong_and_significant_prognostic_factor_in,corresponding_cohort
we,separately_assessed,their_ability_in_their_originally_targeted_populations
signature,is_strong_prognostic_factor_in,cohort
subtype-specific_signature,is_strong_and_significant_prognostic_factor_in,corresponding_cohort
we,assessed,their_ability_of_prognosis_prediction_in_their_originally_targeted_populations
signature,is_strong_independent_prognostic_factor_in,corresponding_cohort
we,summarized_signatures_with,significant_prognostic_value
We,identify,signatures
signature,is_strong_independent_prognostic_factor_in,cohort
Breast_cancer,is_disease_with,variable_mechanisms
Breast_cancer,is_very_complex_disease_with,variable_mechanisms
we,separately_assessed,their_ability_of_prognosis_prediction_in_their_targeted_populations_of_breast_cancer
we,separately_assessed,their_ability_in_their_targeted_populations_of_breast_cancer
collected_signatures,predict,outcomes_of_estrogen_positive
subtype-specific_signature,is_strong_independent_factor_in,cohort
we,assessed,their_ability_of_prognosis_prediction_in_their_targeted_populations_of_breast_cancer
we,summarized,representative_gene-expression-based_signatures
signature,is_strong_factor_in,cohort
we,summarized_signatures_with,significant_value
subtype-specific_signature,is_strong_and_significant_independent_prognostic_factor_in,corresponding_cohort
we,assessed,their_ability_of_prognosis_prediction
subtype-specific_signature,is_independent_prognostic_factor_in,cohort
we,separately_assessed,their_ability_in_their_populations
signature,is_strong_and_significant_prognostic_factor_in,cohort
signature,is_independent_factor_in,cohort
signature,is_factor_in,cohort
we,assessed,their_ability_in_their_populations_of_breast_cancer
Breast_cancer,is_complex_and_heterogeneous_disease_with,variable_mechanisms
subtype-specific_signature,is_strong_independent_prognostic_factor_in,cohort
Breast_cancer,is_complex_disease_with,variable_mechanisms_of_carcinogenesis
we,separately_assessed,their_ability_in_their_originally_targeted_populations_of_breast_cancer
we,summarized,representative_signatures
we,assessed,their_ability_of_prognosis_prediction_in_their_originally_targeted_populations_of_breast_cancer
subtype-specific_signature,is,prognostic_factor
we,separately_assessed,their_ability_of_prognosis_prediction_in_their_populations
we,assessed,their_ability
collected_signatures,were,designed
subtype-specific_signature,is_independent_prognostic_factor_in,corresponding_cohort
strong_independent_prognostic_factor,is_in,corresponding_cohort
Breast_cancer,is_complex_disease_with,molecular_mechanisms
Breast_cancer,is_complex_disease_with,variable_molecular_mechanisms
Breast_cancer,is_complex_and_heterogeneous_disease_with,molecular_mechanisms
cancer,is,complex
collected_signatures,predict,outcomes_of_estrogen_receptor_positive
we,separately_assessed,their_ability_of_prognosis_prediction_in_their_populations_of_breast_cancer
subtype-specific_signature,is_strong_and_significant_independent_factor_in,cohort
Breast_cancer,is_complex_and_heterogeneous_disease_with,mechanisms_of_carcinogenesis
signature,is_factor_in,corresponding_cohort
Breast_cancer,is_complex_and_heterogeneous_disease_with,molecular_mechanisms_of_carcinogenesis
Breast_cancer,is_disease_with,molecular_mechanisms
Breast_cancer,is_very_complex_and_heterogeneous_disease_with,mechanisms
signature,is_independent_prognostic_factor_in,cohort
patients,is_with,breast_cancer
subtype-specific_signature,is_independent_factor_in,corresponding_cohort
signature,is_independent_prognostic_factor_in,corresponding_cohort
we,assessed,their_ability_of_prognosis_prediction_in_their_populations_of_breast_cancer
identification,may_enable,diagnosis_of_breast_cancer
identification,may_enable,treatment
Breast_cancer,is_disease_with,variable_molecular_mechanisms_of_carcinogenesis
Breast_cancer,is_very_complex_disease_with,variable_mechanisms_of_carcinogenesis
subtype-specific_signature,is,factor
Breast_cancer,is_very_complex_and_heterogeneous_disease_with,variable_mechanisms
we,separately_assessed,their_ability_in_their_targeted_populations
signature,is,prognostic_factor
subtype-specific_signature,is_independent_factor_in,cohort
complex_disease,is_with,variable_molecular_mechanisms_of_carcinogenesis
Breast_cancer,is_very_complex_and_heterogeneous_disease_with,molecular_mechanisms_of_carcinogenesis
Breast_cancer,is_disease_with,mechanisms_of_carcinogenesis
we,summarized,several_representative_signatures
signature,is,prognostic
Breast_cancer,is_very_complex_disease_with,variable_molecular_mechanisms_of_carcinogenesis
We,identify,prognostic_signatures
subtype-specific_signature,is,strong_independent_factor
their_ability,is_in,their_originally_targeted_populations_of_breast_cancer
Breast_cancer,is_disease_with,mechanisms
we,assessed,their_ability_in_their_targeted_populations
we,assessed,their_ability_in_their_targeted_populations_of_breast_cancer
Breast_cancer,is_very_complex_and_heterogeneous_disease_with,variable_molecular_mechanisms
signature,is,strong_independent_factor
we,summarized_with,prognostic_value
Breast_cancer,is,disease
Breast_cancer,is_complex_disease_with,variable_molecular_mechanisms_of_carcinogenesis
we,summarized,signatures
subtype-specific_signature,is_strong_and_significant_prognostic_factor_in,cohort
subtype-specific_signature,is,independent_factor
higher_resolution,is_in,risk_stratification
signature,is,strong_prognostic_factor
we,assessed,their_ability_of_prognosis_prediction_in_their_targeted_populations
collected_signatures,predict,outcomes
we,summarized_with,significant_value
Breast_cancer,is_complex_disease_with,mechanisms_of_carcinogenesis
we,assessed,their_ability_in_their_populations
signature,is,strong_independent_prognostic_factor
identification,may_enable,effective_diagnosis_of_breast_cancer
signature,is,strong_factor
Breast_cancer,is_complex_disease_with,mechanisms
subtype-specific_signature,is_strong_and_significant_independent_factor_in,corresponding_cohort
we,summarized_signatures_with,value
we,summarized_with,significant_prognostic_value
We,identify,subtype-specific_prognostic_signatures
subtype-specific_signature,is_strong_independent_prognostic_factor_in,corresponding_cohort
Breast_cancer,is_complex_and_heterogeneous_disease_with,mechanisms
signature,is_strong_and_significant_independent_prognostic_factor_in,corresponding_cohort
signature,is,independent_prognostic_factor
subtype-specific_signature,is_strong_factor_in,corresponding_cohort
Breast_cancer,is_complex_disease_with,variable_mechanisms
Breast_cancer,is_very_complex_disease_with,mechanisms
Breast_cancer,is_very_complex_disease_with,mechanisms_of_carcinogenesis
Breast_cancer,is,complex_disease
we,summarized,several_representative_gene-expression-based_signatures
signature,is_prognostic_factor_in,cohort
neuroma,is_rare_clinical_entity_with,cases
breast,neuroma_of_is,rare_entity_with_few_cases_having_reported
breast,Traumatic_neuroma_of_is,clinical_entity_with_cases_having_reported_to_date
Traumatic_neuroma,is_rare_entity_with,few_cases
may_indicative,obtain,definitive_diagnosis
breast,neuroma_of_is,very_rare_entity_with_only_cases
neuroma,presenting_with,neuropathic_breast_pain
Traumatic_breast_neuromas,are_very_rare_benign_lesions,have_reported_mainly_after_mastectomy
Conservative_treatment,is_feasible_in,properly_selected_cases
breast_neuromas,are_rare_benign_lesions,have_reported_after_mastectomy
breast,neuroma_of_is,rare_clinical_entity_with_only_cases_having_reported
neuroma,is,clinical
We,present,very_rare_case
breast,Traumatic_neuroma_of_is,rare_entity_with_only_few_cases_having_reported_to_date
Traumatic_neuroma,is,very_rare_entity_with_few_cases_having_reported_to_date
neuroma,is_rare_entity_with,few_cases
breast,Traumatic_neuroma_of_is,clinical_entity_with_cases
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_few_cases_having_reported
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_few_cases
breast,Traumatic_neuroma_of_is,rare_entity_with_only_cases_having_reported
breast,neuroma_of_is,entity_with_few_cases_having_reported
traumatic_neuroma,presenting_with,refractory_breast_pain
We,present,rare_case_of_traumatic_breast_neuroma
Conservative_treatment,is,feasible_in_properly_selected_cases_after_tissue_sampling
imaging_features,may,may_indicative_of_benign_lesion_excision
breast,neuroma_of_is,entity_with_cases_having_reported
breast,neuroma_of_is,entity_with_cases
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_cases_having_reported_to_date
treatment,is,feasible_in_selected_cases_with_asymptomatic_neuromas_after_accurate_tissue_sampling
breast,Traumatic_neuroma_of_is,entity_with_only_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,clinical_entity_with_few_cases
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_only_few_cases_having_reported_to_date
may_indicative,is,necessary
necessity,consider_neuroma_in,differential_diagnosis_in_patients
Traumatic_breast_neuromas,are_benign_lesions,have_reported_after_mastectomy
Traumatic_neuroma,is,rare_entity_with_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,very_rare_entity_with_only_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,very_rare_entity_with_only_cases_having_reported
neuroma,is,very_rare_entity_with_few_cases_having_reported
neuroma,is,very_rare_entity_with_only_cases_having_reported
treatment,is_feasible_in,properly_selected_cases_with_neuromas
Traumatic_neuroma,is,very_rare_entity_with_only_cases_having_reported
breast,neuroma_of_is,rare_clinical_entity_with_only_few_cases_having_reported
We,present,case
neuroma,is_very_rare_entity_with,few_cases
treatment,is,feasible_in_properly_selected_cases_with_neuromas_after_tissue_sampling
Conservative_treatment,is,feasible_in_cases_with_asymptomatic_neuromas_after_tissue_sampling
Conservative_treatment,is_feasible_in,selected_cases_with_neuromas
breast,neuroma_of_is,entity_with_only_few_cases_having_reported
neuroma,is,rare_clinical_entity_with_only_cases_having_reported
breast,Traumatic_neuroma_of_is,rare_entity_with_few_cases_having_reported_to_date
case,underlines,necessity
neuroma,is,entity_with_cases_having_reported_to_date
necessity,consider,neuroma
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_only_cases_having_reported
We,herein_present,rare_case
Conservative_treatment,is,feasible_in_selected_cases_with_neuromas_after_tissue_sampling
Traumatic_neuroma,is,entity_with_only_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_only_cases
neuroma,is_entity_with,cases
breast_neuromas,are_lesions,have_reported_after_mastectomy
necessity,consider_neuroma_in,diagnosis_in_patients_with_history
neuroma,is,clinical_entity
Traumatic_neuroma,is,rare_entity
necessity,consider_neuroma_in,diagnosis
lesion,be_missed_on,imaging_investigations
high_index,is,required
neuroma,is,rare_clinical_entity_with_few_cases_having_reported
Traumatic_neuroma,is_very_rare_clinical_entity_with,few_cases
neuroma,is,clinical_entity_with_only_cases_having_reported_to_date
breast,neuroma_of_is,very_rare_entity_with_only_few_cases
treatment,is,feasible_in_selected_cases_after_accurate_tissue_sampling
neuroma,is,rare_clinical_entity_with_cases_having_reported_to_date
neuroma,is_rare_entity_with,cases
traumatic_neuroma,presenting_with,neuropathic_breast_pain
Traumatic_neuroma,is,clinical_entity_with_only_cases_having_reported_to_date
breast,neuroma_of_is,rare_entity_with_only_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,rare_entity_with_only_few_cases_having_reported
Conservative_treatment,is_feasible_in,cases
breast,neuroma_of_is,entity
patients,is_with,history_of_breast_surgery
Traumatic_neuroma,is,rare_clinical_entity_with_cases_having_reported_to_date
breast,neuroma_of_is,clinical_entity_with_few_cases_having_reported_to_date
Traumatic_neuroma,is,clinical_entity_with_cases_having_reported
breast,Traumatic_neuroma_of_is,very_rare_entity_with_few_cases_having_reported
breast,Traumatic_neuroma_of_is,very_rare_entity_with_only_few_cases_having_reported_to_date
neuroma,is,clinical_entity_with_only_cases_having_reported
breast,Traumatic_neuroma_of_is,entity_with_only_cases
treatment,is,feasible_in_properly_selected_cases_with_asymptomatic_neuromas_after_accurate_tissue_sampling
Conservative_treatment,is,feasible_in_properly_selected_cases_after_accurate_tissue_sampling
breast,neuroma_of_is,rare_entity_with_only_few_cases
Conservative_treatment,is,feasible_in_cases_with_neuromas_after_accurate_tissue_sampling
Traumatic_neuroma,is,very_rare_entity_with_only_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,clinical_entity_with_only_few_cases_having_reported
We,herein_present,very_rare_case_of_traumatic_breast_neuroma
imaging_features,may,may_indicative_of_lesion_surgical_excision
lesion,may,may_small
neuroma,is,clinical_entity_with_cases_having_reported
breast,neuroma_of_is,very_rare_clinical_entity_with_few_cases
neuroma,is,clinical_entity_with_few_cases_having_reported_to_date
breast,neuroma_of_is,rare_entity
neuroma,is,very_rare_entity_with_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,entity
Traumatic_neuroma,is,rare_entity_with_only_few_cases_having_reported
breast,Traumatic_neuroma_of_is,clinical_entity
treatment,is,feasible_in_selected_cases_with_asymptomatic_neuromas_after_tissue_sampling
neuroma,is_entity_with,only_few_cases
neuroma,is,rare_entity_with_only_cases_having_reported_to_date
breast_neuromas,are_very_rare_benign_lesions,have_reported_after_mastectomy
Traumatic_neuroma,is_very_rare_clinical_entity_with,cases
Traumatic_neuroma,is,rare_entity_with_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,very_rare_entity_with_few_cases
breast,neuroma_of_is,very_rare_entity_with_only_few_cases_having_reported
neuroma,presenting_with,breast_pain
evaluation,are,discussed
Conservative_treatment,is,feasible_in_selected_cases_with_asymptomatic_neuromas_after_tissue_sampling
rare_clinical_entity,is_with,only_few_cases_having_reported_to_date
breast_neuromas,are_very_rare_lesions,have_reported_after_mastectomy
neuroma,is,very_rare_entity_with_few_cases_having_reported_to_date
neuroma,is,very_rare_entity_with_only_few_cases_having_reported
breast,Traumatic_neuroma_of_is,entity_with_only_cases_having_reported_to_date
treatment,is,feasible_in_selected_cases_with_neuromas_after_accurate_tissue_sampling
necessity,consider,presenting_with_refractory_neuropathic_breast_pain
breast,Traumatic_neuroma_of_is,entity_with_only_few_cases
neuroma,is_rare_entity_with,only_few_cases
breast,Traumatic_neuroma_of_is,very_rare_entity_with_cases
Traumatic_neuroma,is,rare_clinical_entity
breast,neuroma_of_is,rare_clinical_entity_with_only_few_cases_having_reported_to_date
Traumatic_breast_neuromas,are_lesions,have_reported_mainly_after_mastectomy
Traumatic_neuroma,is,very_rare_clinical_entity_with_only_few_cases_having_reported_to_date
treatment,is_feasible_after,tissue_sampling
necessity,consider_in,differential_diagnosis
breast,neuroma_of_is,rare_entity_with_only_cases_having_reported
Traumatic_neuroma,is_clinical_entity_with,only_few_cases
Traumatic_neuroma,is,rare_clinical_entity_with_cases_having_reported
We,present,rare_case_of_breast_neuroma
treatment,is_feasible_in,cases
breast,neuroma_of_is,clinical_entity_with_few_cases_having_reported
treatment,is_feasible_in,properly_selected_cases_with_asymptomatic_neuromas
high_index,is_required,may_small
We,herein_present_case_in,patient
necessity,consider_in,diagnosis_in_patients_with_history_of_breast_surgery
Traumatic_neuroma,is,very_rare_clinical_entity_with_cases_having_reported
breast,neuroma_of_is,clinical_entity
neuroma,is,rare_entity
neuroma,is_clinical_entity_with,only_few_cases
treatment,is_feasible_in,selected_cases
Traumatic_breast_neuromas,are_lesions,have_reported
breast,neuroma_of_is,very_rare_clinical_entity_with_few_cases_having_reported
breast,neuroma_of_is,very_rare_clinical_entity_with_only_cases
breast,neuroma_of_is,very_rare_entity
breast,neuroma_of_is,rare_clinical_entity_with_cases_having_reported_to_date
neuroma,is,clinical_entity_with_few_cases_having_reported
Our_literature_review,yielded,only_35_cases_of_breast_neuromas
Traumatic_neuroma,is,rare_entity_with_only_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,entity_with_few_cases
breast,neuroma_of_is,clinical_entity_with_only_few_cases_having_reported
Traumatic_breast_neuromas,are_rare_lesions,have_reported_mainly_after_mastectomy
We,herein_present,very_rare_case
treatment,is_feasible_in,properly_selected_cases
necessity,consider,presenting_with_neuropathic_breast_pain
breast,neuroma_of_is,rare_clinical_entity_with_only_few_cases
breast,neuroma_of_is,clinical_entity_with_only_cases_having_reported
Traumatic_breast_neuromas,are_benign_lesions,have_reported_mainly_after_mastectomy
breast,Traumatic_neuroma_of_is,clinical_entity_with_only_cases_having_reported
breast,neuroma_of_is,rare_entity_with_few_cases_having_reported_to_date
We,present_case_in,postmenopausal_patient
breast,Traumatic_neuroma_of_is,clinical_entity_with_only_few_cases
neuroma,is,very_rare_entity_with_only_cases_having_reported_to_date
Traumatic_neuroma,is,clinical_entity_with_only_few_cases_having_reported_to_date
Traumatic_breast_neuromas,are_lesions,have_reported_after_mastectomy
Conservative_treatment,is,feasible_in_cases_after_tissue_sampling
breast,neuroma_of_is,very_rare_entity_with_cases
breast,Traumatic_neuroma_of_is,clinical_entity_with_only_few_cases_having_reported_to_date
Traumatic_neuroma,is,clinical_entity_with_few_cases_having_reported_to_date
neuroma,is,very_rare_clinical_entity_with_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,entity_with_few_cases_having_reported_to_date
breast,neuroma_of_is,clinical_entity_with_few_cases
Traumatic_neuroma,is_very_rare_entity_with,only_few_cases
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_only_few_cases
breast,Traumatic_neuroma_of_is,very_rare_entity_with_only_few_cases
breast,neuroma_of_is,very_rare_clinical_entity_with_cases_having_reported_to_date
neuroma,is_clinical_entity_with,cases
breast,neuroma_of_is,entity_with_few_cases
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_few_cases_having_reported_to_date
breast,neuroma_of_is,entity_with_cases_having_reported_to_date
treatment,is,feasible_in_cases_with_asymptomatic_neuromas_after_accurate_tissue_sampling
neuroma,is_very_rare_clinical_entity_with,only_cases
Traumatic_neuroma,is,rare_clinical_entity_with_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,entity_with_cases_having_reported
breast,Traumatic_neuroma_of_is,very_rare_entity_with_cases_having_reported_to_date
necessity,consider_neuroma_in,diagnosis_in_patients_with_history_of_breast_surgery
Traumatic_neuroma,is,very_rare_entity_with_only_cases_having_reported_to_date
treatment,is_feasible_in,cases_with_asymptomatic_neuromas
Traumatic_neuroma,is,very_rare_entity_with_only_few_cases_having_reported
breast_neuromas,are_rare_benign_lesions,have_reported
We,herein_present,rare_case_of_breast_neuroma
neuroma,is_very_rare_clinical_entity_with,few_cases
breast,Traumatic_neuroma_of_is,rare_entity_with_few_cases
neuroma,is,very_rare_clinical_entity_with_only_cases_having_reported
We,present,rare_case
neuroma,is,rare_entity_with_few_cases_having_reported_to_date
Traumatic_neuroma,is,clinical_entity_with_cases_having_reported_to_date
breast_neuromas,are_very_rare_lesions,have_reported
treatment,is,feasible_in_properly_selected_cases_after_accurate_tissue_sampling
breast,Traumatic_neuroma_of_is,entity_with_cases
Traumatic_neuroma,is_rare_clinical_entity_with,only_cases
Conservative_treatment,is,feasible_in_properly_selected_cases_with_neuromas_after_tissue_sampling
Traumatic_neuroma,is_entity_with,few_cases
selected_cases,is_with,asymptomatic_neuromas
Our_literature_review,yielded,only_35_cases
breast,neuroma_of_is,very_rare_clinical_entity_with_only_few_cases_having_reported
neuroma,presenting_with,refractory_breast_pain
neuroma,is_entity_with,few_cases
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_only_few_cases_having_reported
Traumatic_breast_neuromas,are_rare_benign_lesions,have_reported
breast,Traumatic_neuroma_of_is,clinical_entity_with_only_cases
Traumatic_neuroma,is,clinical_entity_with_few_cases_having_reported
breast,Traumatic_neuroma_of_is,entity_with_cases_having_reported_to_date
neuroma,is_entity_with,only_cases
breast,neuroma_of_is,rare_entity_with_few_cases
Traumatic_neuroma,is,entity_with_cases_having_reported_to_date
necessity,consider_neuroma_in,differential_diagnosis
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_only_cases
Traumatic_neuroma,is,rare_entity_with_only_cases_having_reported
Conservative_treatment,is_feasible_in,cases_with_neuromas
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_only_few_cases_having_reported_to_date
Traumatic_neuroma,is,rare_entity_with_cases_having_reported
Traumatic_neuroma,is,entity_with_only_cases_having_reported
Conservative_treatment,is_feasible_after,tissue_sampling
neuroma,is,entity_with_only_few_cases_having_reported_to_date
neuroma,is_rare_entity_with,only_cases
Traumatic_neuroma,is_very_rare_clinical_entity_with,only_cases
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_cases
breast,Traumatic_neuroma_of_is,rare_clinical_entity
neuroma,is,rare_clinical_entity_with_only_few_cases_having_reported_to_date
Traumatic_breast_neuromas,are_very_rare_lesions,have_reported_mainly_after_mastectomy
breast,neuroma_of_is,very_rare_entity_with_few_cases_having_reported
neuroma,is,very_rare_entity_with_only_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,rare_entity_with_only_cases
may_indicative,obtain,diagnosis
necessity,consider_in,differential_diagnosis_in_patients_with_history
lesion,may,may_too_small
neuroma,is_very_rare_entity_with,only_few_cases
breast,Traumatic_neuroma_of_is,very_rare_entity_with_only_cases
treatment,is_feasible_in,cases_with_neuromas
neuroma,is,entity_with_only_cases_having_reported
breast,neuroma_of_is,rare_clinical_entity_with_only_cases
Traumatic_neuroma,is,rare_clinical_entity_with_few_cases_having_reported
breast,neuroma_of_is,clinical_entity_with_cases
diagnosis,rule_out,breast_cancer
breast,neuroma_of_is,entity_with_only_few_cases_having_reported_to_date
Conservative_treatment,is,feasible_in_selected_cases_after_tissue_sampling
breast,neuroma_of_is,very_rare_entity_with_cases_having_reported_to_date
breast_neuromas,are_lesions,have_reported
neuroma,is,very_rare_clinical_entity_with_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_cases_having_reported
treatment,is,feasible_in_cases_with_neuromas_after_accurate_tissue_sampling
necessity,consider_in,differential_diagnosis_in_patients
necessity,consider,presenting_with_breast_pain
neuroma,is,entity_with_cases_having_reported
Traumatic_neuroma,is,clinical_entity_with_only_cases_having_reported
neuroma,is,very_rare_clinical_entity_with_only_few_cases_having_reported_to_date
neuroma,is_clinical_entity_with,few_cases
Traumatic_neuroma,is_rare_entity_with,cases
Conservative_treatment,is_feasible_in,selected_cases
Traumatic_neuroma,is,rare_clinical_entity_with_only_few_cases_having_reported
breast_neuromas,are_benign_lesions,have_reported_mainly_after_mastectomy
breast_neuromas,are_rare_benign_lesions,have_reported_mainly_after_mastectomy
Conservative_treatment,is_feasible_in,selected_cases_with_asymptomatic_neuromas
breast,neuroma_of_is,rare_entity_with_only_few_cases_having_reported
We,herein_present,case_of_breast_neuroma
neuroma,is,rare_clinical_entity_with_cases_having_reported
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_only_few_cases
breast,neuroma_of_is,rare_clinical_entity_with_only_cases_having_reported_to_date
treatment,is,feasible_in_properly_selected_cases_with_asymptomatic_neuromas_after_tissue_sampling
neuroma,is,rare
Traumatic_neuroma,is_rare_clinical_entity_with,few_cases
Traumatic_neuroma,is,entity_with_few_cases_having_reported
breast,Traumatic_neuroma_of_is,rare_entity_with_cases_having_reported
breast,neuroma_of_is,clinical_entity_with_only_few_cases_having_reported_to_date
neuroma,is,very_rare_clinical_entity_with_cases_having_reported
breast,neuroma_of_is,clinical_entity_with_only_cases_having_reported_to_date
Traumatic_neuroma,is_very_rare_entity_with,few_cases
high_index,is_required,may_too_small
neuroma,is_very_rare_clinical_entity_with,only_few_cases
breast,neuroma_of_is,entity_with_only_few_cases
treatment,is,feasible_in_properly_selected_cases_with_neuromas_after_accurate_tissue_sampling
lesion,be,missed
Traumatic_breast_neuromas,are_very_rare_lesions,have_reported_after_mastectomy
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_few_cases
Conservative_treatment,is,feasible
breast,neuroma_of_is,rare_entity_with_cases
neuroma,is_very_rare_clinical_entity_with,cases
necessity,consider_neuroma_in,differential_diagnosis_in_patients_with_history
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_few_cases_having_reported
Traumatic_breast_neuromas,are_very_rare_lesions,have_reported
neuroma,is,rare_entity_with_cases_having_reported
neuroma,is,very_rare_clinical_entity_with_only_few_cases_having_reported
Traumatic_neuroma,is,very_rare_clinical_entity_with_only_cases_having_reported_to_date
breast,neuroma_of_is,very_rare_clinical_entity_with_few_cases_having_reported_to_date
necessity,consider,presenting_with_refractory_breast_pain
breast_neuromas,are_very_rare_benign_lesions,have_reported
Traumatic_breast_neuromas,are_very_rare_benign_lesions,have_reported_after_mastectomy
neuroma,is,very_rare_entity
neuroma,is_clinical_entity_with,only_cases
Conservative_treatment,is_feasible_in,properly_selected_cases_with_asymptomatic_neuromas
Traumatic_neuroma,is,very_rare_entity_with_few_cases_having_reported
neuroma,is,very_rare_clinical_entity_with_only_cases_having_reported_to_date
traumatic_neuroma,presenting_with,breast_pain
breast,Traumatic_neuroma_of_is,very_rare_entity
Traumatic_neuroma,is,very_rare_clinical_entity_with_only_few_cases_having_reported
breast,neuroma_of_is,very_rare_clinical_entity_with_cases_having_reported
breast,neuroma_of_is,very_rare_clinical_entity
Traumatic_neuroma,is,rare_clinical_entity_with_only_cases_having_reported
treatment,is,feasible_in_cases_after_tissue_sampling
breast,neuroma_of_is,very_rare_entity_with_few_cases_having_reported_to_date
breast,neuroma_of_is,rare_clinical_entity_with_few_cases
We,present_case_in,patient
breast,neuroma_of_is,clinical_entity_with_only_cases
necessity,consider_neuroma_in,diagnosis_in_patients
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_cases_having_reported
Traumatic_neuroma,is,rare_clinical_entity_with_only_cases_having_reported_to_date
breast,neuroma_of_is,clinical_entity_with_only_few_cases
Traumatic_neuroma,is,rare_entity_with_only_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,rare_entity_with_cases
Our_literature_review,yielded,only_35_cases_of_traumatic_breast_neuromas
Conservative_treatment,is,feasible_in_cases_with_asymptomatic_neuromas_after_accurate_tissue_sampling
breast,neuroma_of_is,rare_clinical_entity_with_few_cases_having_reported
Traumatic_neuroma,is_very_rare_entity_with,cases
We,present,very_rare_case_of_breast_neuroma
Conservative_treatment,is,feasible_in_cases_after_accurate_tissue_sampling
neuroma,is,rare_entity_with_only_cases_having_reported
breast,neuroma_of_is,rare_entity_with_only_cases_having_reported_to_date
Conservative_treatment,is_feasible_after,accurate_tissue_sampling
breast,neuroma_of_is,very_rare_entity_with_only_cases_having_reported_to_date
Conservative_treatment,is,feasible_in_cases_with_neuromas_after_tissue_sampling
Traumatic_neuroma,is,very_rare_clinical_entity
imaging_features,may,may_indicative_of_lesion_excision
We,herein_present,case
Traumatic_neuroma,is,very_rare_entity_with_cases_having_reported_to_date
imaging_features,may,may_indicative_of_benign_lesion_surgical_excision
Conservative_treatment,is_feasible_in,cases_with_asymptomatic_neuromas
neuroma,is,entity_with_only_few_cases_having_reported
neuroma,is_very_rare_entity_with,cases
breast,neuroma_of_is,clinical_entity_with_cases_having_reported
breast,neuroma_of_is,very_rare_clinical_entity_with_only_cases_having_reported_to_date
Traumatic_neuroma,is,entity
Conservative_treatment,is,feasible_in_selected_cases_after_accurate_tissue_sampling
necessity,consider_in,diagnosis_in_patients
Traumatic_neuroma,is_rare_entity_with,only_few_cases
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_only_cases_having_reported_to_date
neuroma,is,entity
imaging_features,may,may_indicative
definitive_diagnosis,rule_out,breast_cancer
treatment,is,feasible_in_selected_cases_with_neuromas_after_tissue_sampling
breast,Traumatic_neuroma_of_is,entity_with_only_cases_having_reported
breast,neuroma_of_is,entity_with_only_cases
Traumatic_breast_neuromas,are_rare_benign_lesions,have_reported_after_mastectomy
breast,neuroma_of_is,very_rare_entity_with_only_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,rare_entity_with_few_cases_having_reported
breast,Traumatic_neuroma_of_is,rare_entity
Conservative_treatment,is,feasible_in_selected_cases_with_asymptomatic_neuromas_after_accurate_tissue_sampling
breast,neuroma_of_is,entity_with_few_cases_having_reported_to_date
We,herein_present,case_of_traumatic_breast_neuroma
treatment,is,feasible
Conservative_treatment,is,feasible_in_properly_selected_cases_with_neuromas_after_accurate_tissue_sampling
breast,neuroma_of_is,very_rare_clinical_entity_with_only_few_cases_having_reported_to_date
Traumatic_breast_neuromas,are_rare_lesions,have_reported_after_mastectomy
Traumatic_neuroma,is_very_rare_clinical_entity_with,only_few_cases
We,present,very_rare_case_of_traumatic_breast_neuroma
breast,neuroma_of_is,rare_entity_with_cases_having_reported_to_date
neuroma,is,clinical_entity_with_cases_having_reported_to_date
neuroma,is,very_rare_entity_with_cases_having_reported
Traumatic_neuroma,is_clinical_entity_with,only_cases
Traumatic_breast_neuromas,are_rare_lesions,have_reported
Traumatic_neuroma,is_rare_entity_with,only_cases
We,herein_present,rare_case_of_traumatic_breast_neuroma
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_cases
breast,Traumatic_neuroma_of_is,clinical_entity_with_few_cases_having_reported_to_date
Traumatic_neuroma,is,clinical_entity_with_only_few_cases_having_reported
necessity,consider,traumatic_neuroma
Traumatic_neuroma,is,very_rare_clinical_entity_with_few_cases_having_reported
Traumatic_neuroma,is_clinical_entity_with,few_cases
neuroma,is,rare_clinical_entity_with_only_cases_having_reported_to_date
neuroma,is_rare_clinical_entity_with,only_cases
breast_neuromas,are_very_rare_lesions,have_reported_mainly_after_mastectomy
Conservative_treatment,is,feasible_in_selected_cases_with_neuromas_after_accurate_tissue_sampling
neuroma,is_rare_clinical_entity_with,only_few_cases
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_only_cases_having_reported_to_date
treatment,is,feasible_in_cases_with_asymptomatic_neuromas_after_tissue_sampling
Traumatic_neuroma,is,rare_entity_with_few_cases_having_reported
breast_neuromas,are_benign_lesions,have_reported_after_mastectomy
neuroma,presenting_with,refractory_neuropathic_breast_pain
Traumatic_neuroma,is_entity_with,only_cases
index,is_required,may_too_small
Traumatic_neuroma,is_rare_clinical_entity_with,only_few_cases
Traumatic_breast_neuromas,are_rare_benign_lesions,have_reported_mainly_after_mastectomy
breast,Traumatic_neuroma_of_is,very_rare_entity_with_few_cases_having_reported_to_date
breast,neuroma_of_is,very_rare_clinical_entity_with_only_few_cases
neuroma,is,rare_entity_with_only_few_cases_having_reported_to_date
Conservative_treatment,is_feasible_in,properly_selected_cases_with_neuromas
treatment,is,feasible_in_cases_after_accurate_tissue_sampling
Traumatic_neuroma,is,entity_with_only_few_cases_having_reported
Traumatic_neuroma,is_entity_with,only_few_cases
treatment,is_feasible_after,accurate_tissue_sampling
neuroma,is,rare_clinical_entity_with_only_few_cases_having_reported
breast,neuroma_of_is,very_rare_clinical_entity_with_cases
index,is_required,may_small
breast,Traumatic_neuroma_of_is,rare_entity_with_cases_having_reported_to_date
differential_diagnosis,is_in,patients_with_history_of_breast_surgery
necessity,consider_in,differential_diagnosis_in_patients_with_history_of_breast_surgery
Traumatic_neuroma,is,entity_with_few_cases_having_reported_to_date
necessity,consider_in,diagnosis
breast,Traumatic_neuroma_of_is,clinical_entity_with_few_cases_having_reported
breast,Traumatic_neuroma_of_is,rare_entity_with_only_few_cases
breast,Traumatic_neuroma_of_is,entity_with_only_few_cases_having_reported
Traumatic_neuroma,is,rare_clinical_entity_with_only_few_cases_having_reported_to_date
breast,neuroma_of_is,very_rare_entity_with_only_cases_having_reported
breast,Traumatic_neuroma_of_is,entity_with_few_cases_having_reported
Traumatic_neuroma,is,entity_with_only_few_cases_having_reported_to_date
breast,Traumatic_neuroma_of_is,rare_clinical_entity_with_only_few_cases_having_reported
Traumatic_neuroma,is_rare_clinical_entity_with,cases
breast,neuroma_of_is,rare_clinical_entity_with_cases
Conservative_treatment,is,feasible_in_properly_selected_cases_with_asymptomatic_neuromas_after_tissue_sampling
breast_neuromas,are_very_rare_benign_lesions,have_reported_mainly_after_mastectomy
breast,Traumatic_neuroma_of_is,clinical_entity_with_only_cases_having_reported_to_date
breast_neuromas,are_benign_lesions,have_reported
breast,Traumatic_neuroma_of_is,very_rare_entity_with_cases_having_reported
neuroma,is,rare_entity_with_cases_having_reported_to_date
Traumatic_breast_neuromas,are_very_rare_benign_lesions,have_reported
neuroma,is,very_rare_clinical_entity_with_few_cases_having_reported
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity
breast,neuroma_of_is,very_rare_entity_with_few_cases
breast,Traumatic_neuroma_of_is,clinical_entity_with_cases_having_reported
neuroma,is,entity_with_only_cases_having_reported_to_date
breast_neuromas,are_rare_lesions,have_reported_mainly_after_mastectomy
breast,neuroma_of_is,rare_clinical_entity_with_few_cases_having_reported_to_date
breast,neuroma_of_is,very_rare_entity_with_cases_having_reported
Traumatic_neuroma,is,clinical_entity
neuroma,is,entity_with_few_cases_having_reported
Conservative_treatment,is,feasible_in_properly_selected_cases_with_asymptomatic_neuromas_after_accurate_tissue_sampling
necessity,consider_in,diagnosis_in_patients_with_history
neuroma,is,clinical_entity_with_only_few_cases_having_reported_to_date
neuroma,is,clinical_entity_with_only_few_cases_having_reported
neuroma,is,entity_with_few_cases_having_reported_to_date
Traumatic_neuroma,is_very_rare_entity_with,only_cases
We,present,case_of_breast_neuroma
Traumatic_neuroma,is,very_rare_clinical_entity_with_cases_having_reported_to_date
neuroma,is_very_rare_entity_with,only_cases
breast_neuromas,are_lesions,have_reported_mainly_after_mastectomy
We,present,case_of_traumatic_breast_neuroma
Traumatic_neuroma,is_entity_with,cases
Traumatic_breast_neuromas,are_benign_lesions,have_reported
Traumatic_neuroma,is,entity_with_cases_having_reported
breast,neuroma_of_is,entity_with_only_cases_having_reported_to_date
index,is,required
Traumatic_neuroma,is,very_rare_entity_with_cases_having_reported
neuroma,is,rare_clinical_entity
postmenopausal_patient,is_with,history_of_breast-conserving_surgery
neuroma,is,rare_entity_with_only_few_cases_having_reported
neuroma,is,rare_entity_with_few_cases_having_reported
neuroma,is_rare_clinical_entity_with,few_cases
breast,neuroma_of_is,clinical_entity_with_cases_having_reported_to_date
Traumatic_neuroma,is_clinical_entity_with,cases
breast,neuroma_of_is,rare_clinical_entity_with_cases_having_reported
treatment,is_feasible_in,selected_cases_with_asymptomatic_neuromas
necessity,consider,presenting
breast,Traumatic_neuroma_of_is,very_rare_clinical_entity_with_only_cases_having_reported
neuroma,is,rare_clinical_entity_with_few_cases_having_reported_to_date
We,herein_present_case_in,postmenopausal_patient
breast,neuroma_of_is,very_rare_clinical_entity_with_only_cases_having_reported
breast,neuroma_of_is,rare_entity_with_only_cases
treatment,is,feasible_in_cases_with_neuromas_after_tissue_sampling
breast,neuroma_of_is,entity_with_only_cases_having_reported
traumatic_neuroma,presenting_with,refractory_neuropathic_breast_pain
Traumatic_neuroma,is,very_rare_clinical_entity_with_few_cases_having_reported_to_date
breast,neuroma_of_is,rare_entity_with_cases_having_reported
treatment,is_feasible_in,selected_cases_with_neuromas
definitive_diagnosis,rule_out,recurrent_breast_cancer
breast,Traumatic_neuroma_of_is,very_rare_entity_with_only_few_cases_having_reported
necessity,consider_neuroma_in,differential_diagnosis_in_patients_with_history_of_breast_surgery
diagnosis,rule_out,recurrent_breast_cancer
breast_neuromas,are_rare_lesions,have_reported
Diagnostic_evaluation,are,discussed
Traumatic_neuroma,is,very_rare_entity
Traumatic_neuroma,is,very_rare_clinical_entity_with_only_cases_having_reported
treatment,is,feasible_in_properly_selected_cases_after_tissue_sampling
We,herein_present,very_rare_case_of_breast_neuroma
breast,neuroma_of_is,rare_clinical_entity
treatment,is,feasible_in_selected_cases_after_tissue_sampling
breast_neuromas,are_rare_lesions,have_reported_after_mastectomy
neuroma,is,very_rare_clinical_entity
breast,Traumatic_neuroma_of_is,rare_entity_with_only_cases_having_reported_to_date
